zanamivir profile

Zanamivir is a neuraminidase inhibitor that is used to treat influenza A and B infections. It was first synthesized in the early 1990s and is a highly potent antiviral agent that works by preventing the release of new virus particles from infected cells. Zanamivir is available as an inhaled powder and is typically administered twice daily for 5 days. It is well tolerated and has a favorable safety profile. Zanamivir is effective in reducing the duration of influenza symptoms and preventing complications, such as pneumonia. It is particularly important for individuals at high risk of influenza complications, such as the elderly, young children, and those with underlying medical conditions. Zanamivir is studied extensively to understand its antiviral mechanism, optimize its use, and explore its potential in combination therapies. Research also investigates its efficacy against emerging influenza strains and its potential for use in pandemic preparedness.'

Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	60855
CHEMBL ID	222813
CHEBI ID	50663
SCHEMBL ID	9501
MeSH ID	M0217195

Synonym
BIDD:GT0349
bdbm4934
(2r,3r,4s)-4-carbamimidamido-3-acetamido-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
HY-13210
CHEMBL222813 ,
gr-121167
AKOS015841013
gr-121167x
gg-167
4-guanidino-neu5ac2en
5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-d-glycero-d-galacto-non-2-enonic acid
GNA ,
zmr ,
C08095
zanamivir
139110-80-8
gr121167x
gg167
4-guanidino-neueac2en
5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-d-glycero-d-galacto-non-2-enonic acid
relenza
(2r,3r,4s)-3-acetamido-4-guanidino-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
zanamavir
1A4G
4-guanidino-2,4-dideoxy-2,3-dehydro-n-acetylneuraminic acid
DB00558
5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-d-glycero-d-galacto-non-2-enonic acid
gana
(2r,3r,4s)-3-(acetylamino)-4-carbamimidamido-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
2QWE
zanamivir (usp/inn)
relenza (tn)
D00902
NCGC00164561-01
hsdb 7437
gr 121167x
5-acetylamino-2,6-anhydro-4-guanidino-3,4,5-trideoxy-d-galacto-non-enoic acid
gana (inhibitor)
d-glycero-d-galacto-non-2-enonic acid, 5-(acetylamino)-4-(aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-
2,3-didehydro-2,4-dideoxy-4-guanidino-n-acetyl-d-neuraminic acid
4-guanidino-2,4-dideoxy-2,3-didehydro-n-acetylneuraminic acid
zanamivir [usan:inn:ban]
2,3-didehydro-2,4-dideoxy-4-guanidinyl-n-acetylneuraminic acid
4-guanidino-2-deoxy-2,3-didehydro-n-acetylneuraminic acid
gg 167
CHEBI:50663 ,
5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-d-glycero-d-galacto-non-2-enonic acid
(2r,3r,4s)-3-acetamido-4-(diaminomethylideneamino)-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
(2r,3r,4s)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid hydrate
A807485
bdbm50330326
(4s,5r,6r)-5-acetylamino-4-guanidino-6-((1r,3r)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
(4s,5r,6r)-5-acetylamino-4-guanidino-6-((1r,2r)-1,2,3-trihydroxy-propy)-5,6-dihydro-4h-pyran-2-carboxylic acid
(4s,5r,6r)-5-acetamido-4-(diaminomethyleneamino)-6-((1r,2r)-1,2,3-trihydroxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
(4s,5r,6r)-5-acetylamino-4-guanidino-6-((1r,2r)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
4-diaminomethylamino-3-methylcarboxamido-2-(1,2,3-trihydroxypropyl)-(3r)-3,4-dihydro-2h-6-pyrancarboxylic acid(zanamivir)
5-acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid(zanamivir)
(4s,5r,6r)-5-acetylamino-4-guanidino-6-((r)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
(4s,5r,6r)-5-acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
zanamivi
5-acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
5-formylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
dtxcid503749
tox21_112190
cas-139110-80-8
dtxsid0023749 ,
AKOS015994539
unii-l6o3xi777i
l6o3xi777i ,
d-glycero-d-galacto-non-2-enonic acid, 5-(acetylamino)-4-((aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-
zanamivir [mart.]
zanamivir [hsdb]
zanamivir [inn]
zanamivir [who-dd]
zanamivir [mi]
zanamivir [orange book]
zanamivir [usp monograph]
zanamivir [vandf]
zanamivir [usp-rs]
zanamivir [usan]
CS-0631
S3007
Z0023
551942-41-7
SCHEMBL9501
NCGC00164561-02
tox21_112190_1
BS-1017
5-acetylamino-4-guanidino-6-(1,2,3-trihydroxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic acid
4 guanidino 2 deoxy 2,3 didehydro n acetylneuraminic acid
acid, 4-guanidino-2-deoxy-2,3-didehydro-n-acetylneuraminic
4 guanidino neu5ac2en
Q-201942
(2r,3r,4s)-3-acetamido-4-((diaminomethylene)amino)-2-((1r,2r)-1,2,3-trihydroxypropyl)-3,4-dihydro-2h-pyran-6-carboxylic acid
AB01566897_01
mfcd00866966
(2r,3r,4s)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
zanamivir, united states pharmacopeia (usp) reference standard
zanamivir, >=98% (hplc)
zanamivir for assay, europepharmacopoeia (ep) reference standard
zanamivir for system suitability, european pharmacopoeia (ep) reference standard
139110-80-8 (free base)
zanamivirhydrate
zanamivir (relenza)
(2r,3r,4s)-3-acetamido-4-guanidino-2-((1r,2r)-1,2,3-trihydroxypropyl)-3,4-dihydro-2h-pyran-6-carboxylic acid
Q146075
d-glycero-d-galacto-non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-
NCGC00164561-08
CCG-267828
C72554
NCGC00164561-11
dectova
gtpl12307
EN300-26991905
(2r,3r,4s)-3-(acetylamino)-4-{[amino(imino)methyl]amino}-2-[(1r,2r)-1,2,3-trihydroxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid
j05ah01
zanamivir (usp-rs)
zanamivir (usp monograph)
5-acetamido-4-guanidino-2,3,4,5-tetradeoxy-d-glycero-d-galacto-non-2-enopyranosonic acid
(2r,3r,4s)-3-(acetylamino)-4-carbamimidamido-2-((1r,2r)-1,2,3-trihydroxypropyl)-3,4-dihydro-2h-pyran-6-carboxylic acid
zanamivirum
zanamivir (mart.)
5-(acetylamino)-4-

Excerpt	Reference	Relevance
"Zanamivir (ZA) is a potent anti-influenza drug, but it cannot be administrated orally because of the hydrophilic carboxylate and guanidinium groups. "	( Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir. Cheng, YS; Fang, JM; Lee, PS; Liu, KC; Wang, SY; Wong, CH, 2011)	2.09
"Zanamivir is a neuraminidase inhibitor effective against influenza A and B viruses. "	( Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019. Jayabalan, T; Joshi, A; Miller, I; Oliver, A; Peppercorn, A; Wang-Jairaj, J; Zammit-Tabona, P, 2022)	3.61
"Zanamivir is a potent and highly selective inhibitor of influenza neuraminidase in which the inhibition of this enzyme prevents the virus from infecting other cells and specifically prevents release of the new virion from the host cell membrane. "	( Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. Barth, A; Collins, J; Hossain, M; Okour, M; Peppercorn, A; Roberts, G; Shortino, D; Watson, HA; Yates, P; Zuo, P, 2020)	2.24
"Zanamivir is a neuraminidase (NA) inhibitor used for the treatment of influenza. "	( Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. Furukawa, H; Murayama, M; Soutome, T; Watanabe, A; Yates, PJ, 2015)	2.11
"Zanamivir (Za) is a highly polar and hydrophilic antiviral drug used for the treatment of influenza A viruses. "	( Online solid phase extraction liquid chromatography using bonded zwitterionic stationary phases and tandem mass spectrometry for rapid environmental trace analysis of highly polar hydrophilic compounds - Application for the antiviral drug Zanamivir. Appelblad, P; Blum, KM; Fedorova, G; Gillman, A; Järhult, J; Lindberg, RH; Pulit-Prociak, J; Söderström, H, 2015)	2.04
"Zanamivir is a potent inhibitor of H5N1, attains high lung concentrations immediately on administration, distributes into plasma at antiviral concentrations, has a low propensity for generating resistant virus, and retains activity against H275Y oseltamivir-resistant virus."	( Treatment options for H5N1: lessons learned from the H1N1 pandemic. Reece, PA, 2010)	1.08
"Zanamivir is a potent competitive inhibitor of the neuraminidase glycoprotein, which is essential in the infective cycle of influenza A and B viruses. "	( Spotlight on zanamivir in influenza. Cheer, SM; Wagstaff, AJ, 2002)	2.13
"Zanamivir is an appropriate alternative for influenza outbreak control among institutionalized vaccinated elderly."	( Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. Ambrozaitis, A; Binder, E; Daly, J; Drinka, P; Elliott, M; Flack, N; Gravenstein, S; Hammond, J; Kandel, R; Keene, O; Krause, P; McElhaney, J; Osterweil, D; Schilling, M; Shult, P, )	1.29
"Zanamivir is a novel antiviral agent developed for the treatment and prevention of influenza when administered by the oral inhaled route."	( Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Bethell, R; Daniel, M; Dines, GD, 1998)	1.27
"Zanamivir is a potent inhibitor of influenza A and B virus neuraminidases and is active topically in experimental and natural human influenza. "	( Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Calfee, DP; Cass, LM; Hayden, FG; Lobo, M; Peng, AW, 1999)	2.02
"Zanamivir is a well tolerated drug. "	( Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Bye, A; Cass, LM; Efthymiopoulos, C, 1999)	2.07
"Zanamivir is a novel inhibitor of the enzyme neuraminidase, a surface glycoprotein essential for the replication of type A and B influenza viruses. "	( Zanamivir: a review of its use in influenza. Dunn, CJ; Goa, KL, 1999)	3.19
"Zanamivir is a highly selective neuraminidase (NA) inhibitor with demonstrated clinical efficacy against influenza A and B virus infections. "	( Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Barnett, JM; Cadman, A; Candlin, A; Claas, EC; De Groot, R; Dempsey, M; Fenton, RJ; Gor, D; Lewis, AP; Morley, PJ; Osterhaus, AD; Owens, IJ; Rimmelzwaan, GF; Tisdale, M; Walters, M, 2000)	3.19
"Zanamivir is a potent and specific inhibitor of influenza A and B virus neuraminidase, that is now approved for the treatment, and is currently under development for the prophylaxis of influenza. "	( Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Bye, A; Cass, LM; Gunawardena, KA; Macmahon, MM, 2000)	1.96
"Zanamivir is a minimal modification of the natural ligand (Neu5Ac) of the enzyme."	( A novel approach to antiviral therapy for influenza. Colman, PM, 1999)	1.02
"Zanamivir is a neuraminidase inhibitor, the first of a new class of drugs with potent, specific antiviral activity against influenza A and B. "	( Effect of zanamivir on duration and resolution of influenza symptoms. Monto, AS; Moult, AB; Sharp, SJ, 2000)	2.15
"Zanamivir is a potent competitive inhibitor of the neuraminidase glycoprotein, which is essential in the infective cycle of influenza A and B viruses. "	( Zanamivir: an update of its use in influenza. Cheer, SM; Wagstaff, AJ, 2002)	3.2

Excerpt	Reference	Relevance
"Zanamivir has not been shown to reduce the incidence of influenza complications, whether used as prevention or cure. "	( Zanamivir: new indication. Influenza: in children as in adults, symptom relief or vaccination. , 2008)	3.23
"Zanamivir has been shown to inhibit both human and avian influenza viral neuraminidases (NAs) and has been approved in several countries for the treatment and prophylaxis of influenza infection. "	( Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Klimov, A; Mungall, BA; Xu, X, 2003)	2
"Zanamivir has similar performance."	( Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Demicheli, V; Di Pietrantonj, C; Jefferson, TO; Jones, M; Rivetti, D, 2006)	1.06
"Zanamivir treatment has been shown to reduce the severity and duration of naturally occurring, uncomplicated influenza illness in adults."	( New approaches to influenza chemotherapy. Neuraminidase inhibitors. Calfee, DP; Hayden, FG, 1998)	1.02

Excerpt	Reference	Relevance
"Zanamivir treatment within 24 and 24 - 48 h of illness onset in index cases, respectively, reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those not receiving treatment."	( Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment. Nishiura, H; Oshitani, H, 2011)	1.3
"Zanamivir-treated patients had an excess of outpatient visits (16.9% vs 14.5%; RR, 1.16; 95% CI, 1.02-1.33) and antibiotic use (16.3% vs 14.8%; RR, 1.10; 95% CI, 0.97-1.26), although the RRs were modest."	( The effect of zanamivir treatment on influenza complications: a retrospective cohort study. Ajene, AN; Cole, JA; Cook, SE; Loughlin, JE; Rosenberg, DM; Walker, AM, 2002)	1.4
"Zanamivir treatment has been shown to reduce the severity and duration of naturally occurring, uncomplicated influenza illness in adults."	( New approaches to influenza chemotherapy. Neuraminidase inhibitors. Calfee, DP; Hayden, FG, 1998)	1.02
"Zanamivir-treated patients returned to normal activities significantly faster and took significantly fewer relief medications than placebo-treated patients."	( Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Barzilai, A; Behre, U; Hammond, J; Hedrick, JA; Henderson, FW; Keene, O; Reilly, L, 2000)	2.47
"Zanamivir treatment reduced absenteeism, improved patient productivity and well-being, and reduced the additional use of healthcare resources in patients with influenza."	( Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Aoki, FY; Edmundson, S; Fleming, DM; Griffin, AD; Lacey, LA, 2000)	2.15
"Zanamivir treatment was also associated with a significant reduction in time to alleviation of symptoms with no use of relief medication."	( Effect of zanamivir on duration and resolution of influenza symptoms. Monto, AS; Moult, AB; Sharp, SJ, 2000)	1.43
"Zanamivir-treated high-risk patients had a treatment benefit of 2.5 days compared with those given placebo (P = .015). "	( Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Campion, K; Keene, O; Lalezari, J; Silagy, C, 2001)	3.2
"Treatment with zanamivir prevented the infection and abrogated the local cytokine and chemokine responses."	( Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. Alvord, WG; Calfee, DP; Cass, LM; Fritz, RS; Hayden, FG; Peng, AW; Straus, SE; Strober, W, 1999)	0.85
"Treatment with zanamivir for this high risk population results in an incremental cost of $A14.20 per day of symptoms avoided in the base case. "	( Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Cates, SC; Griffin, AD; Lamb, SC; Mauskopf, JA; Neighbors, DM; Rutherford, C, 2000)	0.97
"Treatment with zanamivir for this population is cost effective based on an $A78,000 per QALY benchmark."	( Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Cates, SC; Griffin, AD; Lamb, SC; Mauskopf, JA; Neighbors, DM; Rutherford, C, 2000)	0.96

Excerpt	Reference	Relevance
"The current study evaluated whether intranasal administration of the sialic acid analog 4-guanidino-Neu5Ac2en (GG167), an inhibitor of influenza virus neuraminidase, was effective and safe in either preventing or treating experimental human influenza."	( Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Betts, RF; Esinhart, JD; Hayden, FG; Hussey, EK; Lobo, M; Treanor, JJ, )	0.13
"Direct respiratory administration of the selective neuraminidase inhibitor GG167 appears safe and effective for both prevention and early treatment of experimental influenza."	( Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Betts, RF; Esinhart, JD; Hayden, FG; Hussey, EK; Lobo, M; Treanor, JJ, )	0.13
"In adults with influenza A or B virus infections, direct administration of a selective neuraminidase inhibitor, zanamivir, to the respiratory tract is safe and reduces symptoms if begun early."	( Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. Aoki, FY; Bohnen, AM; Fleming, DM; Hayden, FG; Hirst, HM; Keene, O; Nicholson, KG; Osterhaus, AD; Treanor, JJ; Wightman, K, 1997)	0.76
" Systemic plasma concentrations 1336-fold those achieved in clinical use were not associated with significant adverse effects."	( Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Bethell, R; Daniel, M; Dines, GD, 1998)	0.55
" The adverse event profiles were similar for zanamivir and placebo."	( Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. , 1998)	0.81
" Serious adverse events from an ongoing Japanese clinical programme are also reported."	( Zanamivir: a review of clinical safety. Elliott, M; Freund, B; Gravenstein, S; Miller, I, 1999)	1.75
" Zanamivir was well tolerated, with an adverse event profile similar to that of placebo."	( Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. Fleming, DM; Keene, ON; Mäkelä, MJ; Man, CY; Pauksens, K; Rostila, T; Webster, A, 2000)	1.45
" The incidence and pattern of adverse events was similar in zanamivir and placebo recipients."	( Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Gravenstein, S; Johnston, SL; Loeschel, E; Webster, A, 2001)	2
" However, the data presented are somewhat limited by the paucity of good quality adverse event data available."	( Safety of neuraminidase inhibitors for influenza. Del Mar, C; Jones, M, 2006)	0.33
" All adverse events (AEs) occurring after the first dose of study medication were recorded."	( Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Bettis, R; Hampel, FC; Harris, J; Henderson, FW; Kudule, L; LaForce, C; Man, CY; McElhaney, JE; Tisdale, M; Webster, A; Yates, P, 2007)	0.63
"Randomized, placebo-controlled, double-blind human trials of extended-duration NAI chemoprophylaxis that reported outcomes of laboratory-confirmed influenza or adverse events."	( Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Bravata, DM; Gould, MK; Holty, JE; Khazeni, N; Stave, CD; Uyeki, TM, 2009)	0.35
" No study was powered to detect rare adverse events, and none included diverse racial groups, children, immunocompromised patients, or individuals who received live attenuated influenza virus vaccine."	( Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Bravata, DM; Gould, MK; Holty, JE; Khazeni, N; Stave, CD; Uyeki, TM, 2009)	0.35
" All the reported adverse events, such as rash, nasal ache, muscle ache, nausea, diarrhea, headache, occurred in less than 1% of subjects."	( An uncontrolled open-label, multicenter study to monitor the antiviral activity and safety of inhaled zanamivir (as Rotadisk via Diskhaler device) among Chinese adolescents and adults with influenza-like illness. Cao, B; Chen, BY; Dong, JP; Gao, Y; Hu, K; Li, XL; Pu, ZH; Shu, YL; Song, SF; Wang, C; Wang, DY; Wang, J; Wei, LQ; Xu, Q; Yu, XM; Yu, YS, 2012)	0.59
" Drowsiness was the most frequent adverse event for both drugs (38% for the oseltamivir group, and 22% for the zanamivir group)."	( Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment. Karabay, O; Tuna, N; Yahyaoğlu, M, )	0.59
"Efficacy (in terms of symptom relief and duration to resumption of work) and adverse events were similar for zanamivir and oseltamivir, but temperature normalization was much more rapid in patients using zanamivir."	( Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment. Karabay, O; Tuna, N; Yahyaoğlu, M, )	0.59
" Adverse events of interest such as abnormal behavior/delirium, dizziness/vertigo, respiratory disorders, shock/syncope, and any other serious events were intensively reviewed by the Safety Evaluation Committee."	( Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Eda, H; Fukushima, M; Nakano, T; Niwa, S; Okumura, A; Tanabe, T; Tsutsumi, H; Yonemochi, R, 2013)	0.39
" A total of 20 adverse events (AEs) were reported (all grade 1) by nine subjects, with no AE reported ≥1× in any treatment group."	( Safety, tolerability and pharmacokinetics of orally inhaled zanamivir: a randomized study comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in healthy adults. Jones, LS; Lou, Y; Ng-Cashin, J; Peppercorn, A; Piscitelli, S; Weller, S, 2013)	0.63
" Primary outcomes included adverse events (AEs), and clinical/laboratory parameters."	( Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. Alvarez-Lerma, F; Brealey, D; Francois, B; Garot, D; Lorente, JA; Man, CY; Mánez, R; Marty, FM; Peppercorn, AF; Thamlikitkul, V; van der Horst, C; Weller, S; Yates, PJ; Zhao, HH, 2014)	0.67
" Overall adverse events (AEs) and serious adverse events (SAEs) were reported in 13 (62%) and 4 (19%) subjects, respectively."	( Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study. Furukawa, H; Murayama, M; Soutome, T; Watanabe, A; Yates, PJ, 2015)	0.67
" Limited, low-quality data suggest NIs are likely safe in general populations and may be safe in pregnant women and children."	( Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. Boikos, C; Caya, C; Delisle, G; Doll, MK; Dolph, M; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N, 2017)	0.46
" Our evidence suggests NIs are likely safe to use in the general population; however, data for children and pregnant women are limited."	( Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. Boikos, C; Caya, C; Delisle, G; Doll, MK; Dolph, M; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N, 2017)	0.46
"We undertook a survey to evaluate the compliance and the tolerability of oseltamivir and zanamivir when they were used as post-exposure prophylaxis among the medical staffs in the 2014-2015 seasons to understand a characteristic of adverse events caused by anti-influenza (flu) agents."	( Adverse events of prophylactic anti-influenza agents in medical staffs. Asai, N; Furui, T; Hagihara, M; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakata, M; Takahashi, T; Yamagishi, Y, 2017)	0.68
" The adverse events caused by oseltamivir were reported by 86 of 382 medical staffs (22."	( Adverse events of prophylactic anti-influenza agents in medical staffs. Asai, N; Furui, T; Hagihara, M; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakata, M; Takahashi, T; Yamagishi, Y, 2017)	0.46
"5% subjects experienced any adverse events due to oseltamivir."	( Adverse events of prophylactic anti-influenza agents in medical staffs. Asai, N; Furui, T; Hagihara, M; Kato, H; Kato, Y; Koizumi, Y; Kurumiya, A; Mikamo, H; Nishiyama, N; Sakata, M; Takahashi, T; Yamagishi, Y, 2017)	0.46
" We recommend that decisions regarding NI use are made in consideration of potential adverse events, particularly for the general population at low risk of complications."	( Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. Boikos, C; Doll, MK; Gore, G; Kraicer-Melamed, H; Quach, C; Winters, N, 2017)	0.46
"7%) participants in the NTZ and placebo groups, respectively, reported serious adverse events."	( Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Araujo-Meléndez, J; Beigel, JH; Galindo-Fraga, A; Gamiño-Arroyo, AE; García-Andrade, LA; Guerrero, ML; Holley, HP; Hunsberger, S; Ibarra-González, V; Kapushoc, H; Llamosas-Gallardo, B; Martínez-López, J; McCarthy, S; Moreno-Espinosa, S; Ramírez-Venegas, A; Roldán-Aragón, Y; Ruiz-Palacios, GM; Smolskis, MC, 2019)	0.51
" The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs."	( Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews. Han, N; Kim, IW; Oh, JM, 2020)	0.56
"We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report database."	( Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance. Hosohata, K; Iida, T; Inada, A; Iwanaga, K; Kambara, H; Nakatsuji, T; Niinomi, I; Oyama, S; Uchida, M; Ueno, S; Wakabayashi, T, 2022)	0.72

Excerpt	Reference	Relevance
" Serum and urine samples were obtained for determination of pharmacokinetic parameters, and nasal washes and throat gargles were performed to assess drug concentrations in the nose and throat."	( Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Bye, A; Cass, LM; Efthymiopoulos, C, 1999)	0.63
" The elimination of zanamivir from the serum was a first-order process with a half-life of approximately 2 hours and, at 16 L, the volume of distribution was similar to that of extracellular water."	( Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Bye, A; Cass, LM; Efthymiopoulos, C, 1999)	0.95
" No significant differences in pharmacokinetic parameters were observed when demographic variables, indices of infection, or concurrent medication use were considered in either phase I or phase II population analyses."	( A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. Hussey, EK; Moore, KH; Peng, AW, 2000)	0.57
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" CS-8958 disappeared from plasma with a half-life of about 2 hours, although laninamivir was slowly eliminated from the body, lasting for even up to 144 hours after administration with a half-life of about 3 days."	( Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. Ishizuka, H; Okabe, H; Yoshiba, S; Yoshihara, K, 2010)	0.36
" After intratracheal administration of CS-8958, plasma R-125489 concentration was slowly eliminated, and its half-life (14."	( Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats. Hoshi, M; Kobayashi, N; Koyama, K; Murai, T; Nakai, N; Okazaki, O; Takahashi, M; Takakusa, H; Yamamura, N, 2010)	0.36
" The area under the concentration-time curve extrapolated to infinity (AUC(0-inf)), maximum concentration (C(max)), and time to C(max) of CS-8958 did not change with the degree of renal impairment, whereas the half-life (t(1/2)) of CS-8958 increased with increasing renal insufficiency."	( Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958. Ishizuka, H; Okabe, H; Yoshiba, S; Yoshihara, K, 2011)	0.37
" In a companion paper, we show that the time above the 50% effective concentration (time>EC(50)) is the pharmacodynamic (PD) index predicting the inhibition of viral replication by intravenous zanamivir."	( Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Adams, JR; Brown, AN; Bulitta, JB; Drusano, GL; Kulawy, R; McSharry, JJ; Weng, Q, 2011)	0.81
" It is not known if there is any pharmacokinetic interaction between the two drugs."	( An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. Chueasuwanchai, S; Day, NP; Fukuda, C; Hanpithakpong, W; Jittamala, P; Leowattana, W; Lindegardh, N; Pan-Ngum, W; Panapipat, S; Permpunpanich, S; Phakdeeraj, A; Pukrittayakamee, S; Singhasivanon, P; Stepniewska, K; White, NJ, 2011)	0.58
" Each zanamivir regimen was administered to six healthy subjects with serial pharmacokinetic sampling."	( Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Gauvin, J; Gould, E; Jones, L; Lovern, M; Ng-Cashin, J; Rodvold, KA; Shelton, MJ, 2011)	2.29
" The laninamivir concentration in ELF decreased with a longer half-life than that in plasma, and it exceeded the 50% inhibitory concentrations for viral neuraminidases at all time points examined for 240 h after the inhalation."	( Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Furuie, H; Ishizuka, H; Okabe, H; Toyama, K; Yoshiba, S, 2012)	0.38
" This study was conducted to evaluate the pharmacokinetic and safety profiles of intravenous zanamivir, an influenza viral neuraminidase inhibitor, in Japanese subjects to further characterize these profiles particularly following relatively high-doses when compared with inhalation doses and to provide reassurance that there are no marked differences with profiles reported for other ethnically different populations."	( The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. Hara, K; Hirama, T; Nohda, S; Shida, Y; Soutome, T, 2013)	0.87
" The pharmacokinetic profile of zanamivir after intravenous administration was consistent with previously reported findings in non-Japanese subjects."	( The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. Hara, K; Hirama, T; Nohda, S; Shida, Y; Soutome, T, 2013)	0.94
" The population pharmacokinetic model also provides insight into the likely kinetics of drug disposition in the respiratory tract following inhaled administration."	( Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Ishizuka, H; Kubo, Y; Yoshihara, K, 2013)	0.39
" Serial blood samples were collected up to 24 h after dose administration (48 h for the severe renal impairment group) to estimate zanamivir serum pharmacokinetic parameters."	( Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment. Jones, LS; Lou, Y; Ng-Cashin, J; Peppercorn, A; Weller, S, 2013)	0.92
" Serial blood samples for pharmacokinetic analysis were collected over a 12-h dose interval on day 5 of each treatment period."	( Safety, tolerability and pharmacokinetics of orally inhaled zanamivir: a randomized study comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in healthy adults. Jones, LS; Lou, Y; Ng-Cashin, J; Peppercorn, A; Piscitelli, S; Weller, S, 2013)	0.63
"The safety and pharmacokinetic results from this study support the use of the Rotacap/Rotahaler presentation, potentially allowing an increased number of zanamivir treatment courses to be supplied in the event of an influenza pandemic."	( Safety, tolerability and pharmacokinetics of orally inhaled zanamivir: a randomized study comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in healthy adults. Jones, LS; Lou, Y; Ng-Cashin, J; Peppercorn, A; Piscitelli, S; Weller, S, 2013)	0.83
" Pharmacokinetic data showed dose adjustments for renal impairment yielded similar zanamivir exposures."	( Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. Alvarez-Lerma, F; Brealey, D; Francois, B; Garot, D; Lorente, JA; Man, CY; Mánez, R; Marty, FM; Peppercorn, AF; Thamlikitkul, V; van der Horst, C; Weller, S; Yates, PJ; Zhao, HH, 2014)	0.89
"Safety, pharmacokinetic and clinical outcome data support further investigation of intravenous zanamivir."	( Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. Alvarez-Lerma, F; Brealey, D; Francois, B; Garot, D; Lorente, JA; Man, CY; Mánez, R; Marty, FM; Peppercorn, AF; Thamlikitkul, V; van der Horst, C; Weller, S; Yates, PJ; Zhao, HH, 2014)	0.88
" The current population pharmacokinetic model based on data from eight studies of subjects treated with the intravenous formulation (125 healthy adults and 533 hospitalized adult and pediatric subjects with suspected or confirmed influenza) suggested a decreased zanamivir clearance in pediatric and renal impairment adult subjects."	( Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. Barth, A; Collins, J; Hossain, M; Okour, M; Peppercorn, A; Roberts, G; Shortino, D; Watson, HA; Yates, P; Zuo, P, 2020)	0.97

Excerpt	Reference	Relevance
"The objective of this study was to assess the potential of zanamivir, a specific inhibitor of influenza A and B virus neuraminidase, to interact with other coadministered therapies in the clinical setting."	( The low potential for drug interactions with zanamivir. Barnett, JM; Daniel, MJ; Pearson, BA, 1999)	0.81
"These data suggest the following: (i) there is no theoretical basis for expecting metabolic interactions between zanamivir and other coadministered compounds; (ii) zanamivir is unlikely to interact with coadministered compounds that are protein bound; and (iii) commonly coadministered drugs will not interfere with the antiviral activity of zanamivir in vivo."	( The low potential for drug interactions with zanamivir. Barnett, JM; Daniel, MJ; Pearson, BA, 1999)	0.77
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35

Excerpt	Reference	Relevance
" While readily bioavailable by systemic routes, it was poorly bioavailable by the oral route."	( Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Dempsey, MH; Penn, CR; Ryan, DM; Ticehurst, J, 1994)	0.29
" The study of absolute oral bioavailability had an open design."	( Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Bye, A; Cass, LM; Efthymiopoulos, C, 1999)	0.63
" The absolute oral bioavailability of zanamivir was low, averaging 2%."	( Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Bye, A; Cass, LM; Efthymiopoulos, C, 1999)	0.9
" Less than 5% of drug was excreted unchanged in urine within 8 hours of inhalation, confirming the low bioavailability of zanamivir after pulmonary delivery."	( Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Brown, J; Bye, A; Cass, LM; Fayinka, S; Johansson, CJ; Newman, SP; Pickford, M, 1999)	0.75
" This may be attributed to the low systemic bioavailability of zanamivir, which is given by oral inhalation, direct to the primary site of viral replication."	( Zanamivir: a review of clinical safety. Elliott, M; Freund, B; Gravenstein, S; Miller, I, 1999)	1.99
" Zanamivir is delivered by inhalation because of its low oral bioavailability whereas oseltamivir is administered by mouth."	( Influenza virus neuraminidase inhibitors. Gubareva, LV; Hayden, FG; Kaiser, L, 2000)	1.22
" Poor bioavailability of zanamivir in the peripheral lungs might have been limiting treatment efficacy in such an immunocompromised patient."	( Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Lorin, V; Manuguerra, JC; Medeiros, R; Naffakh, N; Rameix-Welti, MA; Ribaud, P; Scieux, C; Socie, G; van der Werf, S, 2007)	1.03
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" On the basis of these results, liposomes are able to improve permeability of zanamivir across the Caco-2 monolayers, thereby possibly enhancing oral bioavailability of zanamivir."	( Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir. Boonyapiwat, B; Kunastitchai, S; Sarisuta, N, 2011)	0.82
" The poor oral bioavailability is attributed to the high polarity (cLogP ∼ -5) resulting from the polar and zwitterionic nature of zanamivir."	( Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Amidon, GL; Dahan, A; Gupta, D; Gupta, SV; Hilfinger, J; Lee, KD; Sun, J; Tsume, Y, 2011)	0.83
" The absolute oral bioavailability of these compounds was lower than 12%."	( Development of oseltamivir phosphonate congeners as anti-influenza agents. Chen, CA; Chen, CL; Cheng, TJ; Cheng, YS; Fang, JM; Hsieh, WC; Hu, OY; Huang, PW; Jan, JT; Lin, WH; Shie, JJ; Tarbet, EB; Wang, SY; Weinheimer, S; Wong, CH, 2012)	0.38
"We have demonstrated that simple formulations composed of the parent drug in combination with generally regarded as safe (GRAS) permeability enhancers are capable of dramatically increasing the absolute bioavailability of zanamivir."	( Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. Devalapally, H; Holmes, EH; Li, L; Ostrander, GK; Perdue, ML, 2013)	0.83
" Among different prodrug strategies pursued, a simple amidoxime ethyl ester (9) exhibited a superior PK profile with an oral bioavailability of 31% (rats), which is comparable to oseltamivir (36%)."	( Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. Clement, B; Koch, O; Kotthaus, J; Müller-Fielitz, H; Raasch, W; Riebling, L; Schade, D; Schmidtke, M; Seidel, N, 2014)	0.4
" The lower bioavailability may explain the lower toxicity of zanamivir compared to oseltamivir."	( Neuraminidase inhibitors for preventing and treating influenza in adults and children. Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ, 2014)	0.64
"For the treatment of seasonal flu and possible pandemic infections the development of new anti-influenza drugs that have good bioavailability against a broad spectrum of influenza viruses including the resistant strains is needed."	( From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Cheng, CK; Fang, JM; Shie, JJ; Tsai, CH, 2014)	0.4
" Unfortunately, low oral bioavailability precludes their development as second generation neuraminidase inhibitors for treating influenza as this leaves them unsuitable for use in an oral formulation."	( Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. Arns, S; Bourque, E; Dercho, S; Galey, A; Gusti, V; Liggins, R; Paquette, J; Ross, F; Sun, S; Tan, J; Udechukwu, J; Webb, M; Withers, SG; Zisman, N, 2015)	0.42
" The most promising prodrug candidates, amidoxime ester 7 and N-hydroxyguanidine ester 8, were subjected to in vivo bioavailability studies."	( Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability. Clement, B; Hoffmann, A; Kotthaus, J; Müller-Fielitz, H; Raasch, W; Riebling, L; Schade, D; Schmidtke, M, 2015)	1.86
" The bioavailability was 116% relative to Relenza®."	( Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder. Cai, X; Mei, X; Xie, X; Yang, Y; Yang, Z; Yu, F; Zhang, T, 2016)	0.66
" The lipophilic acyl substituents were verified to improve cell permeability, and may also improve the bioavailability of acylguanidine compounds."	( Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses. Cheng, TJ; Cheng, YE; Chiu, DC; Fang, JM; Hsu, PH; Jan, JT; Lee, PS; Tsai, KC; Wu, KL, 2018)	0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Other measures of illness were reduced by approximately 50% to 70% in the GG167 dosing groups."	( Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Betts, RF; Esinhart, JD; Hayden, FG; Hussey, EK; Lobo, M; Treanor, JJ, )	0.13
" In the absence of dose-limiting toxicity in animal studies and in an attempt to identify target-organ toxicity, the high dosage level in all repeat dose studies was selected to be the maximum practicable."	( Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Bethell, R; Daniel, M; Dines, GD, 1998)	0.55
" Compliance with the once-daily dosage was high."	( Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. Crisp, A; Elliott, MJ; Herlocher, ML; Hinson, JM; Monto, AS; Robinson, DP, 1999)	1.75
"The proposed total daily dosage of zanamivir by oral inhalation is 20 mg."	( Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Bye, A; Cass, LM; Efthymiopoulos, C; Marsh, J, 1999)	0.82
" In addition, these data may be useful in the design of prophylactic protocols for humans, in that the dosing schedule may only need to be intermittent to provide protection."	( Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract. Crossman, L; Fenton, RJ; Gower, D; Morley, PJ; Owens, IJ; Parry, S; Wong, T, 1999)	0.54
" Furthermore there was no apparent treatment difference over the 14 day dosing period in FEV1 data (90% CI: -0."	( Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Bye, A; Cass, LM; Gunawardena, KA; Macmahon, MM, 2000)	0.52
" Oral administration of a dosage of 1 mg/kg of body weight/day of RWJ-270201 for 5 days (beginning 4 h preinfection) showed efficacy in the murine model of influenza virus infection as determined by lethality and weight loss protection."	( Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Ananth, SL; Andries, K; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Horn, LL; Hutchison, TL; Kellog, DL; Kotian, PL; Lin, T; Montgomery, JA; Parker, CD, 2001)	0.53
" We conducted two studies to assess the pharmacokinetics and protective efficacy of a reduced frequency dosing regimen of topical zanamivir."	( Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Calfee, DP; Hayden, FG; Hussey, EK; Lobo, M; Peng, AW, 1999)	0.77
"Randomised controlled, double blind trials that were published in English, had data available before 31 December 2001, evaluated treatment or prevention of naturally occurring influenza with zanamivir or oseltamivir (if given using the formulation and dosage licensed for clinical use), and reported at least one end point of relevance."	( Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Abrams, KR; Cooper, NJ; Nicholson, KG; Sutton, AJ; Turner, D; Wailoo, A, 2003)	0.51
" Because no prospective data exist on the efficacy of these agents in humans for H5N1 strains, the dosage and duration of therapy in adults and children may differ from those documented to be effective for epidemic influenza strains."	( Antiviral therapy and prophylaxis for influenza in children. , 2007)	0.34
" Factors which might contribute to this apparently limited efficacy include suboptimal dosing or routes of administration, suboptimal timing of treatment and the inability of antiviral drugs to interfere with immunopathology, and the development of drug resistance."	( Neuraminidase inhibitors and their role in avian and pandemic influenza. Crusat, M; de Jong, MD, 2007)	0.34
" The paper describes mechanism of action of neuraminidase inhibitors (oseltamivir and zanamivir), their main pharmacokinetic features, dosing and side effects."	( [Neuraminidase inhibitors in prophylaxis and treatment of influenza]. Brydak, LB; Nitsch-Osuch, A; Wardyn, AK, 2008)	0.57
" The clinical and laboratory parameters and plasma and urinary concentrations of CS-8958 and laninamivir for 144 hours post dosing were measured."	( Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. Ishizuka, H; Okabe, H; Yoshiba, S; Yoshihara, K, 2010)	0.36
" Further animal studies and human clinical trials are necessary to optimize neuraminidase inhibitor dosing strategies for the treatment of influenza A(H5N1) infections."	( Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Barr, IG; Hurt, AC; Lowther, S; Middleton, D, 2010)	0.62
" Therefore, we performed studies using the in vitro hollow-fiber infection model system to predict optimal dosing regimens for zanamivir against an oseltamivir-sensitive and an oseltamivir-resistant virus."	( Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Adams, JR; Brown, AN; Drusano, GL; Kulawy, R; McSharry, JJ; Weng, Q, 2011)	2.02
" administration of 100 mg, 200 mg, and 600 mg zanamivir, the median zanamivir concentrations in ELF collected 12 h after dosing were 74, 146, and 419 ng/ml, respectively, each higher than the historic mean 50% inhibitory concentrations for the neuraminidases of wild-type strains of influenza A and B viruses."	( Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Gauvin, J; Gould, E; Jones, L; Lovern, M; Ng-Cashin, J; Rodvold, KA; Shelton, MJ, 2011)	2.07
" Maoto granules, a commercial medical dosage form, are made from four plants: Ephedra Herb, Apricot Kernel, Cinnamon Bark, and Glycyrrhiza Root."	( A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza. Ajisaka, K; Ikematsu, H; Kashiwagi, K; Kashiwagi, S; Masui, S; Nabeshima, S; Takeoka, H, 2012)	0.38
" Intranasal administration of low dosage (<1."	( Enhanced anti-influenza agents conjugated with anti-inflammatory activity. Cheng, TJ; Cheng, YS; Fang, JM; Jan, JT; Liu, KC; Wang, SY; Wong, CH; Yang, ST, 2012)	0.38
"Single and 5-day BID repeat dosing of 600 mg were safely administered in Japanese healthy subjects."	( The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males. Hara, K; Hirama, T; Nohda, S; Shida, Y; Soutome, T, 2013)	0.65
" These results suggest that optimal human oral dosage forms of zanamivir should be enteric-coated gelcaps or softgels for intraduodenal release."	( Permeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatment. Devalapally, H; Holmes, EH; Li, L; Ostrander, GK; Perdue, ML, 2013)	0.89
" The processed SPR data was analysed to determine 50% inhibitory concentrations (IC50-spr ), using a log dose-response curve fit."	( A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir. Fairbanks, AJ; Fee, CJ; Fredericks, R; Hall, RJ; Somasundaram, B; Watson, AJ, 2015)	0.61
" Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase."	( Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Chung, HK; Lamb, K; Lin, MZ; Plemper, RK; Weisshaar, M; Yan, D, 2015)	0.42
"Time to clinical response to intravenous zanamivir dosed at 600 mg was not superior to oseltamivir or 300 mg intravenous zanamivir."	( Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Chapman, MJ; Clark, C; Garot, D; Gupta, SK; Husa, P; Jacobs, F; Marty, FM; Merino, E; Peppercorn, AF; Rodriguez-Noriega, E; Shortino, D; Vidal-Puigserver, J; Watson, HA; Yates, PJ, 2017)	1.1
" A single-center, open-label study was conducted to evaluate the plasma and intrapulmonary pharmacokinetics (PK) of laninamivir after a single nebulized administration of LO in healthy male Japanese subjects for identifying a safe and effective dosage regimen for a nebulizer."	( Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects. Furuie, H; Ishizuka, H; Toyama, K, 2018)	0.48
" dosing is necessary to keep the exposure in influenza infected subjects above the 90% inhibitory concentration values of recently circulating viruses over the dosing interval."	( Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. Barth, A; Collins, J; Hossain, M; Okour, M; Peppercorn, A; Roberts, G; Shortino, D; Watson, HA; Yates, P; Zuo, P, 2020)	0.79
"Limited data exist for dosing of zanamivir in the setting of CVVH in the intensive care unit (ICU)."	( Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration. Haringman, JJ; Koch, BC; Ter Horst, PG; Wagenvoort, GH; Wieringa, A, 2023)	1.52
" These results highlight the potential of neuraminidase inhibition for ameliorating endothelial dysfunction in T2D and suggest the current Food and Drug Administration-approved inhaled dosage of zanamivir is insufficient to achieve desired outcomes in humans."	( Neuraminidase inhibition improves endothelial function in diabetic mice. Aroor, AR; Augenreich, MA; Bender, SB; Burr, K; Foote, CA; Ghiarone, T; Manrique-Acevedo, C; Martinez-Lemus, LA; McMillan, NJ; Morales-Quinones, M; Padilla, J; Power, G; Ramirez-Perez, FI; Smith, JA, 2023)	1.1

Role	Description
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor	An antiviral drug targeted at influenza viruses. Its mode of action consists of blocking the function of the viral neuraminidase protein (EC 3.2.1.18), thus preventing the virus from budding from the host cell.
antiviral agent	A substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
guanidines	Any organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GALC protein	Homo sapiens (human)	Potency	0.7079	28.1838	28.1838	28.1838	AID1159614
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	28.1838	0.0123	7.9835	43.2770	AID1346984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Neuraminidase	Influenza B virus (STRAIN B/BEIJING/1/87)	IC50 (µMol)	0.0040	0.0040	0.0040	0.0040	AID977608
Chain A, Neuraminidase	Influenza B virus (STRAIN B/BEIJING/1/87)	IC50 (µMol)	0.0040	0.0040	0.0040	0.0040	AID977608
Chain A, Neuraminidase	Influenza A virus	IC50 (µMol)	0.0040	0.0040	0.0040	0.0040	AID977608
Chain A, Neuraminidase	Influenza A virus	Ki	0.0330	0.0330	98.0110	280.0000	AID977610
Chain A, Neuraminidase	Influenza A virus	Ki	0.0330	0.0330	98.0110	280.0000	AID977610
Chain A, Neuraminidase	Influenza A virus	Ki	0.0330	0.0330	98.0110	280.0000	AID977610
Chain A, NEURAMINIDASE	Influenza A virus	Ki	0.0330	0.0330	98.0110	280.0000	AID977610
Chain A, Neuraminidase	Influenza A virus	Ki	0.0330	0.0330	98.0110	280.0000	AID977610
Neuraminidase	Influenza A virus (A/Turkey/651242/2006(H5N1))	IC50 (µMol)	0.0054	0.0003	0.3103	2.8247	AID1409417; AID1494239; AID1494240; AID560872
Neuraminidase	Influenza A virus (A/Turkey/651242/2006(H5N1))	Ki	0.0010	0.0010	0.0044	0.0079	AID560877
Neuraminidase	Influenza A virus (A/Wilson-Smith/1933(H1N1))	IC50 (µMol)	41.7026	0.0000	0.5035	10.0000	AID1064127; AID1064128; AID1064131; AID1064132; AID1071472; AID1071474; AID1071475; AID1071476; AID1071477; AID1071481; AID1071482; AID1071483; AID1241697; AID1241698; AID1241699; AID1308299; AID1308300; AID1308301; AID1308302; AID1308303; AID1308304; AID1308305; AID1308306; AID1308307; AID1308308; AID1308309; AID1308310; AID1308311; AID1308312; AID1308313; AID1308314; AID1308642; AID1308645; AID1308647; AID1308648; AID1308649; AID1308650; AID1308651; AID1308652; AID1355761; AID1355762; AID1355763; AID1355764; AID1355765; AID1355766; AID1355767; AID1355768; AID1355770; AID1360171; AID1494229; AID1494230; AID1494231; AID1494232; AID1494233; AID1494234; AID1494235; AID1494236; AID1494237; AID1494238; AID1494251; AID1494252; AID1604728; AID343686; AID384920; AID420935; AID420936; AID488375; AID532116; AID542945; AID542946; AID542947; AID542948; AID542949; AID542950; AID542951; AID542952; AID542953; AID542954; AID542955; AID542956; AID542957; AID542958; AID542959; AID542960; AID542961; AID542962; AID542963; AID542964; AID542965; AID542966; AID542967; AID542968; AID542969; AID542970; AID542971; AID542995; AID542996; AID542997; AID542998; AID542999; AID543000; AID543001; AID543002; AID543003; AID543004; AID543006; AID543007; AID543183; AID543184; AID543186; AID543187; AID560874; AID561142; AID561144; AID612400; AID636870; AID667460; AID667579; AID714642; AID722608; AID722609; AID722610
Neuraminidase	Influenza A virus (A/Wilson-Smith/1933(H1N1))	Ki	0.0002	0.0001	1.7868	7.7000	AID314411; AID488379; AID526403; AID560879
Neuraminidase	Influenza A virus (A/duck/Laos/25/2006(H5N1))	IC50 (µMol)	0.0027	0.0001	1.1047	6.0950	AID1355769; AID560875; AID561145
Neuraminidase	Influenza A virus (A/duck/Laos/25/2006(H5N1))	Ki	0.0005	0.0005	0.0008	0.0011	AID560880
Neuraminidase	Influenza A virus (A/Brisbane/59/2007(H1N1))	IC50 (µMol)	0.0276	0.0034	0.1490	0.4510	AID1494249; AID1494250
Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))	IC50 (µMol)	0.0043	0.0005	0.9767	10.0000	AID1355760; AID1368740; AID1368742; AID147346; AID147493; AID147504; AID1604725; AID1886446; AID1895906; AID203357; AID203359; AID203532; AID203533; AID203535; AID203537; AID532114
Neuraminidase	Influenza A virus (A/Wilson-Smith/1933(H1N1))	IC50 (µMol)	0.0017	0.0004	0.1343	0.9930	AID1331612; AID1360170; AID713858; AID714639; AID716614
Neuraminidase	Influenza A virus (A/Memphis/1/1971(H3N2))	IC50 (µMol)	0.0147	0.0001	0.0091	0.0324	AID1368741; AID1494241; AID1494242; AID1604726
Neuraminidase	Influenza B virus (B/Lee/1940)	IC50 (µMol)	0.0809	0.0010	0.4028	10.0000	AID147351; AID147494; AID1494247; AID1494248; AID203371; AID203373; AID203545; AID203546; AID203667
Neuraminidase	Influenza B virus (B/Lee/1940)	Ki	0.0001	0.0001	0.0010	0.0025	AID314410
Neuraminidase	Influenza A virus (A/udorn/1972(H3N2))	IC50 (µMol)	0.0154	0.0154	0.3622	0.5813	AID1626674
Acyl-CoA desaturase 1	Mus musculus (house mouse)	IC50 (µMol)	0.0010	0.0010	0.6830	3.4000	AID1064128
Neuraminidase	Influenza B virus (STRAIN B/VICTORIA/3/85)	IC50 (µMol)	0.0045	0.0040	0.0045	0.0050	AID1795717
Histamine H1 receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.0077	0.0015	1.3072	10.0000	AID1409417
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0074	0.0001	0.5494	8.4000	AID1409416
Sialidase A	Streptococcus pneumoniae	Ki	720.0000	0.1000	2.9283	9.4000	AID1802683
Neuraminidase	Influenza A virus (A/duck/Ukraine/1/1963(H3N8))	IC50 (µMol)	0.0074	0.0074	0.0082	0.0089	AID1409416
Neuraminidase	Influenza A virus (A/RI/5+/1957(H2N2))	IC50 (µMol)	1.4000	0.8000	1.7667	3.1000	AID1129834
Neuraminidase	Influenza A virus (A/udorn/1972(H3N2))	IC50 (µMol)	0.0229	0.0016	0.0091	0.0229	AID714636
Neuraminidase	Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1))	IC50 (µMol)	0.0007	0.0007	0.0025	0.0049	AID560873; AID561143
Neuraminidase	Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1))	Ki	0.0004	0.0004	0.0027	0.0049	AID560878
Neuraminidase	Influenza B virus (B/Perth/211/2001)	IC50 (µMol)	0.0882	0.0089	0.0882	0.1674	AID1494245; AID1494246
Neuraminidase	Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1))	IC50 (µMol)	0.0024	0.0002	0.0013	0.0048	AID560871; AID561141; AID714644
Neuraminidase	Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1))	Ki	0.0005	0.0001	0.0003	0.0005	AID560876
Neuraminidase	Influenza A virus (A/Singapore/1/1957(H2N2))	IC50 (µMol)	0.0070	0.0010	0.0050	0.0170	AID1795717; AID1795726
Neuraminidase	Influenza A virus (A/budgerigar/Hokkaido/1/1977(H4N6))	IC50 (µMol)	0.0228	0.0153	0.0190	0.0228	AID1409413
Neuraminidase	Influenza A virus (A/Aichi/2/1968(H3N2))	IC50 (µMol)	0.0027	0.0016	0.0021	0.0027	AID532115
Integrase	Human immunodeficiency virus 1	IC50 (µMol)	0.0025	0.0005	1.5443	10.0000	AID1886450
Sialidase-4	Homo sapiens (human)	IC50 (µMol)	350.0000	8.3000	8.3000	8.3000	AID1308297; AID1308298; AID1405015; AID1490015; AID1619204; AID1889679; AID532109; AID532113
Sialidase-4	Homo sapiens (human)	Ki	26.0000	1.0000	4.6000	5.8000	AID1405019; AID1490011; AID1619220
Sialidase-3	Homo sapiens (human)	IC50 (µMol)	5.6617	2.4000	5.9980	8.1700	AID1308294; AID1405014; AID1490016; AID1619203; AID532112; AID539786
Sialidase-3	Homo sapiens (human)	Ki	0.6200	0.6200	1.2657	2.2000	AID1405018; AID1490012; AID1619219
Sialidase-2	Homo sapiens (human)	IC50 (µMol)	9.7922	3.9000	6.7333	7.8000	AID1308295; AID1405013; AID1490017; AID1619202; AID1889674; AID1889675; AID1889677; AID532107; AID748614
Sialidase-2	Homo sapiens (human)	Ki	8.5250	5.0000	5.5250	5.7000	AID1405017; AID1490013; AID1619218; AID473065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Neuraminidase	Influenza A virus (A/udorn/1972(H3N2))	Kd	0.0047	0.0047	0.0047	0.0047	AID1626683
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
viral release from host cell	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
glycoprotein catabolic process	Sialidase-4	Homo sapiens (human)
ganglioside catabolic process	Sialidase-4	Homo sapiens (human)
oligosaccharide catabolic process	Sialidase-4	Homo sapiens (human)
negative regulation of neuron projection development	Sialidase-4	Homo sapiens (human)
oligosaccharide catabolic process	Sialidase-1	Homo sapiens (human)
ganglioside catabolic process	Sialidase-1	Homo sapiens (human)
carbohydrate metabolic process	Sialidase-3	Homo sapiens (human)
ganglioside catabolic process	Sialidase-3	Homo sapiens (human)
oligosaccharide catabolic process	Sialidase-3	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Sialidase-3	Homo sapiens (human)
glycosphingolipid catabolic process	Sialidase-3	Homo sapiens (human)
negative regulation of clathrin-dependent endocytosis	Sialidase-3	Homo sapiens (human)
glycoprotein catabolic process	Sialidase-2	Homo sapiens (human)
ganglioside catabolic process	Sialidase-2	Homo sapiens (human)
oligosaccharide catabolic process	Sialidase-2	Homo sapiens (human)
glycosphingolipid catabolic process	Sialidase-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
exo-alpha-sialidase activity	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
peptidase activator activity	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
exo-alpha-sialidase activity	Sialidase-4	Homo sapiens (human)
protein binding	Sialidase-4	Homo sapiens (human)
exo-alpha-(2->3)-sialidase activity	Sialidase-4	Homo sapiens (human)
exo-alpha-(2->6)-sialidase activity	Sialidase-4	Homo sapiens (human)
exo-alpha-(2->8)-sialidase activity	Sialidase-4	Homo sapiens (human)
exo-alpha-sialidase activity	Sialidase-1	Homo sapiens (human)
protein binding	Sialidase-1	Homo sapiens (human)
alpha-sialidase activity	Sialidase-1	Homo sapiens (human)
exo-alpha-(2->3)-sialidase activity	Sialidase-1	Homo sapiens (human)
exo-alpha-(2->6)-sialidase activity	Sialidase-1	Homo sapiens (human)
exo-alpha-(2->8)-sialidase activity	Sialidase-1	Homo sapiens (human)
exo-alpha-sialidase activity	Sialidase-3	Homo sapiens (human)
protein binding	Sialidase-3	Homo sapiens (human)
alpha-sialidase activity	Sialidase-3	Homo sapiens (human)
exo-alpha-(2->3)-sialidase activity	Sialidase-3	Homo sapiens (human)
exo-alpha-(2->6)-sialidase activity	Sialidase-3	Homo sapiens (human)
exo-alpha-(2->8)-sialidase activity	Sialidase-3	Homo sapiens (human)
exo-alpha-sialidase activity	Sialidase-2	Homo sapiens (human)
protein binding	Sialidase-2	Homo sapiens (human)
exo-alpha-(2->3)-sialidase activity	Sialidase-2	Homo sapiens (human)
exo-alpha-(2->6)-sialidase activity	Sialidase-2	Homo sapiens (human)
exo-alpha-(2->8)-sialidase activity	Sialidase-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membrane	Neuraminidase	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
lysosome	Sialidase-4	Homo sapiens (human)
mitochondrial outer membrane	Sialidase-4	Homo sapiens (human)
mitochondrial inner membrane	Sialidase-4	Homo sapiens (human)
lysosome	Sialidase-4	Homo sapiens (human)
endoplasmic reticulum membrane	Sialidase-4	Homo sapiens (human)
plasma membrane	Sialidase-4	Homo sapiens (human)
organelle inner membrane	Sialidase-4	Homo sapiens (human)
neuron projection	Sialidase-4	Homo sapiens (human)
lysosomal lumen	Sialidase-4	Homo sapiens (human)
lysosome	Sialidase-4	Homo sapiens (human)
cytoplasm	Sialidase-4	Homo sapiens (human)
membrane	Sialidase-4	Homo sapiens (human)
extracellular region	Sialidase-1	Homo sapiens (human)
lysosome	Sialidase-1	Homo sapiens (human)
lysosomal membrane	Sialidase-1	Homo sapiens (human)
plasma membrane	Sialidase-1	Homo sapiens (human)
cell junction	Sialidase-1	Homo sapiens (human)
specific granule lumen	Sialidase-1	Homo sapiens (human)
lysosomal lumen	Sialidase-1	Homo sapiens (human)
intracellular membrane-bounded organelle	Sialidase-1	Homo sapiens (human)
extracellular exosome	Sialidase-1	Homo sapiens (human)
lysosome	Sialidase-1	Homo sapiens (human)
cytoplasm	Sialidase-1	Homo sapiens (human)
membrane	Sialidase-1	Homo sapiens (human)
lysosomal membrane	Sialidase-3	Homo sapiens (human)
plasma membrane	Sialidase-3	Homo sapiens (human)
caveola	Sialidase-3	Homo sapiens (human)
external side of plasma membrane	Sialidase-3	Homo sapiens (human)
early endosome membrane	Sialidase-3	Homo sapiens (human)
recycling endosome membrane	Sialidase-3	Homo sapiens (human)
membrane	Sialidase-3	Homo sapiens (human)
lysosome	Sialidase-3	Homo sapiens (human)
cytoplasm	Sialidase-3	Homo sapiens (human)
cytosol	Sialidase-2	Homo sapiens (human)
catalytic complex	Sialidase-2	Homo sapiens (human)
lysosome	Sialidase-2	Homo sapiens (human)
membrane	Sialidase-2	Homo sapiens (human)
cytoplasm	Sialidase-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (917)

Assay ID	Title	Year	Journal	Article
AID1813704	Antiviral activity against Influenza A virus (A/California/07/2009 (H1NI)) harboring NA H275Y mutant infected in dog MDCK cells assessed as reduction in virus replication incubated for 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1494246	Inhibition of Influenza B virus (B/Perth/211/2001) neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1181484	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID716603	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in BALB/c mouse assessed as protection from virus-induced death at 1.2 umol/kg/day, intranasally administered bid on days 1 to 4 and day 0 of infection measured after 12 da	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID131091	Reduction in virus titre taken from mouse infected with Influenza A/Singapore/1/57 at 0.4 mg/kg dose in 7 day mouse influenza prevention assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID565048	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 6250 nM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1813699	Inhibition of Influenza A virus (A/California/07/2009 (H1N1)) neuraminidase N1 H275Y mutant using MUNANA as substrate preincubated for 30 mins followed by substrate addition by fluorescence method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1308307	Inhibition of Influenza A virus (A/duck/Tsukuba/28/2006(H3N8)) neuraminidase N8 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1355795	Cytotoxicity against MDCK cells after 48 hrs by MTT assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID352033	Inhibition of Influenza A virus (A/Singapore/1/1957 (H2N2)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID716610	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in BALB/c mouse assessed as protection from virus-induced death at 12 umol/kg/day, intranasally administered bid on days 1 to 4 and day 0 of infection measured over 14 days	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1903184	Antiviral activity against influenza A virus H5N1 infected in dog MDCK cells assessed as inhibition of viral cytopathic effect incubated for 48 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).
AID133476	Number of virus free mice from total 8 mice infected with Influenza A/Singapore/1/57 after 12.5 mg/kg of intranasal administration for 172 hr prior to viral infection	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1405014	Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID542989	Inhibition of Influenza B virus (B/Aichi/186/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID667460	Inhibition of Influenza A virus (A/Sydney/5/97(H3N2)) recombinant neuraminidase using 2'-(4- methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate after 1 hr by fluorescence assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID1308304	Inhibition of Influenza A virus A/duck/Chiba/13/06(H12N5) neuraminidase N5 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1494238	Inhibition of Influenza A virus (A/chicken/Vietnam/08/2004 (H5N1)) clade 1 neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID203371	Compound was tested for inhibitory concentration against Influenza sialidase type B	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
AID523879	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID460210	Antiviral activity against human influenza A virus A/TW/141/04 (H1N1) in MDCK cells assessed as reduction of virus-induced cytopathic effect	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
AID761713	Inhibition of influenza A virus A/California/04/2009 (pdm09 H1N1) N1 sialidase using fluorogenic substrate 4-methylumbelliferyl N-acetyl-alpha-D-neuraminide preincubated for 15 mins measured after 30 mins by spectrofluorometry	2013	Bioorganic & medicinal chemistry, Aug-15, Volume: 21, Issue:16	Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.
AID543000	Inhibition of Influenza A virus (A/seal/Massachusetts/1/1980(H7N7)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543205	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 166 ug/kg, itn administered 1 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1405016	Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID567586	Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567720	Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID92312	Concentration required for reduction of plaque against influenza A	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID515130	Inhibition of Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant expressed in Sf21 insect cells after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID524856	Antimicrobial activity against Influenza B virus (B/Malaysia/2506/2004) infected itn dosed Mustela putorius furo assessed as nasal viral titer treated after 4 hrs post infection measured after 3 days	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID567607	Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1903201	Antiviral activity against Influenza A virus (A/PR/8/34) H1N1 infected in dog MDCK cells assessed as inhibition of viral cytopathic effect incubated for 48 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).
AID565478	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1308301	Inhibition of Influenza A virus (A/duck/Tsukuba/28/2005(H6N2)) neuraminidase N2 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID565259	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 3,125 nM of zanamivir after 6 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID542993	Inhibition of Influenza B virus (B/Yamagata/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567709	Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1472397	Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) neuraminidase using fetuin as substrate	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID542976	Inhibition of Influenza B virus (B/Yamagata/15/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1355760	Inhibition of Influenza A virus (A/PuertoRico/8/1934(H1N1)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1626683	Binding affinity to zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 E119V/I222L double mutant expressed in baculovirus infected insect cells measured up to 400 sec by surface plasmon resonance analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID515126	Fold resistance, ratio of IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1494232	Inhibition of Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase H274Y mutant using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1626673	Inhibition of recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 expressed in baculovirus infected insect cells using 4-MU-NANA as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1485249	Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID667580	Antiviral activity against Influenza A virus (A/Indonesia/5/2005(H5N1)) X-31 infected in MDCK cells assessed as protective rate against virus-induced cytopathic effect at 5 uM after 2 days by neutral red uptake assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID1494276	Ratio of IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase D197E mutant measured every min for 60 mins to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase D197E mutant preincubated for 60 mins followed by substrate addition measured e	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1308312	Inhibition of Influenza A virus A/Kitakyushu/10/06(H1N1) neuraminidase N1 H274Y mutant activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID565051	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 781 uM of oseltamivir after 10 passage after 48 hrs	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1610156	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID567703	Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1490015	Inhibition of human N-terminal MBP-fused NEU4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID567726	Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID667593	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID565476	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567715	Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1360170	Inhibition of Influenza A virus (A/WSN/1933(H1N1)) wild type neuraminidase using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured for 15 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID1895906	Inhibition of Influenza A virus A/PR/8/1934 (H1N1) neuraminidase using 2(4-methylurnbellifery1)-a-u-acetyl neuraminic acid sodium salt hydrate (4-MUNANA) as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fl	2021	Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24	Identification of C5-NH
AID667594	Terminal half life in Sprague-Dawley rat at 2 mg/kg, iv	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID1368740	Inhibition of Influenza A virus A/PR/8/34(H1N1) sialidase preincubated for 15 mins followed by MUNA substrate addition measured after 15 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Synthesis and anti-influenza virus evaluation of triterpene-sialic acid conjugates.
AID1731311	Selectivity index, ratio of TC50 for MDCK cells to EC50 for antiviral activity against Influenza A virus A/Hebei Xinhua/SWL1106/2017 (H1N1) pdm09 infected in MDCK cells	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID20028	Vss, volume of distribution at steady state at a dose of 50 mg/kg	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID543202	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 166 ug/kg, itn administered 10 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565256	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID722608	Inhibition of influenza A virus (A/Guangdong/376/2001(H1N1)) neuraminidase infected in chick embryo using MUNANA as substrate after 1 hr by spectrophotometric analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID481717	Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay	2010	European journal of medicinal chemistry, May, Volume: 45, Issue:5	QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors.
AID524843	Antimicrobial activity against Influenza B virus (B/Hong Kong/05/1972) infected in BALB/c mouse assessed as increase in mouse survival at 1.1 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID565470	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID352044	Antiviral activity against Influenza B virus (B/Mie/1/93) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID567588	Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1494245	Inhibition of Influenza B virus (B/Perth/211/2001) neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID560874	Inhibition of Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) neuraminidase by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID565050	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 9 passage after 48 hrs b	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565269	Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID203369	Inhibitory concentration by Sialidase inhibitory assay; range- 11-29 ng/mL	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
AID565477	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565246	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1813703	Antiviral activity against Influenza A virus (Avian A/Vietnam/1194/2004 (H5N1)) infected in dog MDCK cells assessed as reduction in virus replication incubated for 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID542945	Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352046	Antiviral activity against Tamiflu-resistant influenza A virus (A/Yokohama/67/2006 (H1N1)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID716601	Antiinflammatory activity in mouse infected with Influenza A virus (A/VietNam/1194/2004(H5N1)) NIBRG-14 assessed as reduction in IL6 level in serum at 12 umol/kg/day, intranasally administered after 72 hrs by ELISA	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1152623	Cytotoxicity against MDCK cells after 72 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12	Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H(5)N(1).
AID524830	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival at 3.3 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1494233	Inhibition of Influenza A virus (A/California/07/09 (H1N1)) neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1071469	Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID283442	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID567618	Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1409414	Inhibition of Influenza A virus A/goose/Guangdong/SH7/2013(H5N1) neuraminidase N1 using fluorogenic MUNANA as substrate preincubated for 10 mins followed by substrate addition measured after 40 to 60 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1071473	Antiviral activity against Influenza A virus H3N2	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID1071466	Antiviral activity against Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) infected in MDCK cells assessed as reduction in virus yield after 48 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID203359	Inhibitory activity against influenza A sialidase (Aichi)	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1355784	Antiviral activity against Influenza A virus A/goose/Guangdong/SH7/2013(H5N1) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID567711	Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1532046	Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/WSN/1933(H1N1))
AID524837	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival at 1.6 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID612400	Inhibition of influenza A/WSN/1933 (H1N1) virus neuraminidase N1 using MUNANA substrate by fluorimetric assay	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID1729968	Inhibition of Influenza A virus (A/California/04/2009(H1N1)) neuraminidase using 4-MU-NANA as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID1485247	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID542977	Inhibition of Influenza B virus (B/Akita/9/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID460206	Antiviral activity against human influenza A virus A/WSN/33 (H1N1) in MDCK cells assessed as reduction of virus-induced cytopathic effect	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
AID532109	Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID1355783	Cytotoxicity against chicken embryo fibroblasts after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID565466	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID560873	Inhibition of Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) neuraminidase by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID567589	Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543007	Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID234904	Relative potency in sialidase inhibitory assay and plaque reduction assay	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
AID203533	Compound was tested for its inhibitory activity against A/PR/8/34 (N1) sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID717280	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID567594	Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID92335	Concentration required for reduction of plaque against influenza B	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.
AID542991	Inhibition of Influenza B virus (B/Sapporo/29/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542964	Inhibition of Influenza A virus (A/Wisconsin/67/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542968	Inhibition of Influenza A virus (A/Saitama/80/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565044	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515127	Selectivity ratio of IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase to IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID565460	Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID24041	t1/2, plasma elimination half life, the time taken for the plasma concentrations to fall by one half, once distribution is complete at a dose of 50 mg/kg	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1355766	Inhibition of Influenza A virus (A/goose/Jiangsu/1306/2014(H5N8)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID542961	Inhibition of Influenza A virus (A/California/07/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352043	Antiviral activity against Influenza A virus (A/Kitakyushu/159/93(H3N2)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1360172	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells expressing wild type neuraminidase assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferation	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID524860	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as reduction in viral titer in lung at 0.17 mg/kg, itn administered 11 hrs post infection measured after 35 hrs post infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID718741	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID565265	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565047	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 1250 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515121	Inhibition of Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase expressed in Sf21 insect cells after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID561143	Inhibition of Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID300564	Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID542962	Inhibition of Influenza A virus (A/New York/55/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID283443	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID565457	Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1889675	Inhibition of NEU2 (unknown origin) using Neu5Acalpha2-6GalbetapNP as substrate incubated for 30 mins	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID1490011	Inhibition of human N-terminal MBP-fused NEU4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every minute for 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID1731306	Inhibition of Influenza A virus A/Puerto Rico/8/1934(H1N1) neuraminidase using MUNANA as substrate measured after 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID271157	Antiviral activity against avian influenza virus H5N1 in MDCK cells measured as reduction in infected cells relative to control	2006	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19	Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.
AID1064132	Inhibition of Influenza A virus H5N1 neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Bifunctional thiosialosides inhibit influenza virus.
AID1626710	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as decrease in lung lesions at 10 mg/kg qd administered intranasally for 7 days starting from 1 day post infection by hematoxylin and eosin staining based microscopic analysi	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID532107	Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID147314	Fold resistance of R292K to compound against neuraminidase in a MUNANA-based enzyme inhibition assay, expressed as the ratio of IC50 of comp. with variant N9 to that of with wild-type N9	2002	Journal of medicinal chemistry, May-23, Volume: 45, Issue:11	Structural studies of the resistance of influenza virus neuramindase to inhibitors.
AID1485244	Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1360193	Half life in human serum at 16 mg	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID524839	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as reduction in viral titer in lung at 14 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID526403	Inhibition of influenza A nuraminidase N1	2010	Journal of medicinal chemistry, Oct-28, Volume: 53, Issue:20	Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles.
AID352037	Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01) (H5N1)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID543001	Inhibition of Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID524844	Antimicrobial activity against Influenza B virus (B/Hong Kong/05/1972) infected in BALB/c mouse assessed as increase in mouse survival at 3.3 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1308642	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID565053	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID718742	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID561142	Inhibition of Influenza A virus (A/Turkey/651242/2006(H5N1)) neuraminidase A119A mutant isolated from virus-infected BALB/c mouse by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID532116	Inhibition of human influenza A virus A/DK/HK/313/4/78(H5N3) neuraminidase by fluorometric method using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID567724	Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID560880	Inhibition of Influenza A virus (A/duck/Laos/25/2006(H5N1)) neuraminidase by Michaelis-Menten equation analysis	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID565461	Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1626699	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as protection against lethal virus challenge by measuring body weight at 20 mg/kg administered intranasally as single dose at 2 hrs post infection me	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1729971	Inhibition of Influenza A virus (A/Chicken/Hebei/UR/2014(H5N2)) neuraminidase using 4-MU-NANA as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID131092	Reduction in virus titre taken from mouse infected with Influenza A/Singapore/1/57 at 1.0 mg/kg dose in 7 day mouse influenza prevention assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1610159	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1485246	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1626676	Inhibition of zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Shanghai/2/2013(H7N9)) Neuraminidase N9 R294K mutant expressed in baculovirus infected insect cells using 4-MU-NANA as substrate preincubated for 30 mins followed by substrate	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1626679	Binding affinity to recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 expressed in baculovirus infected insect cells assessed as dissociation rate constant measured up to 400 sec by surface plasmon resonance analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1368741	Inhibition of Influenza A virus A/Memphis/1/71(H3N2) sialidase preincubated for 15 mins followed by MUNA substrate addition measured after 15 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Synthesis and anti-influenza virus evaluation of triterpene-sialic acid conjugates.
AID1143481	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as increase in survival rate at 0.12 umol/kg/day administered on day 0 intranasally bid prior to viral infection continued for day 1 to day 4 measured on day	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Tamiphosphor monoesters as effective anti-influenza agents.
AID1409411	Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells after 3 days by plaque reduction assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID704188	Inhibition of Influenza A virus sialidase N2 by fluorometric assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Exploring the interactions of unsaturated glucuronides with influenza virus sialidase.
AID524831	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival at 7 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID392530	Antiviral activity against influenza H5N1 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1355765	Inhibition of Influenza A virus (A/duck/Guangdong/674/2014(H5N6)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1409408	Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID561144	Inhibition of Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID203374	Inhibitory activity against sialidase of influenza B	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.
AID1071467	Antiviral activity against Influenza A virus A/Jena/5258/2009(H1N1) infected in MDCK cells assessed as reduction in virus yield after 48 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID1408332	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1736919	Antiviral activity against Influenza A virus (A/Duck/Guangdong/674/2014 (H5N6)) group-2 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hem	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID1181478	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID130242	Compound was tested for concentration of intranasally administered drug (0.5 mg/kg) which reduces virus titer by 90%	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1071472	Inhibition of neuraminidase in Influenza A virus A/Sachsen/6/02(H3N2) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID460214	Antiviral activity against human influenza B virus B/TW/99/07 in MDCK cells assessed as reduction of virus-induced cytopathic	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
AID565260	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 16 uM of zanamivir after 7 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567705	Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1494254	Inhibition of Influenza A virus (A/swine/Shepparton/6/2009 (H1N1)) neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after removal of inhibi	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1626708	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as respiratory epithelium desquamation at 5 mg/kg qd administered intranasally for 7 days starting from 1 day post infection by hematoxylin and eosin	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID283441	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID131093	Reduction in virus titre taken from mouse infected with Influenza A/Singapore/1/57 at 1.6 mg/kg dose in 7 day mouse influenza prevention assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1494236	Inhibition of Influenza A virus (A/swine/Shepparton/6/2009 (H1N1)) neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID515129	Inhibition of Influenza B virus B/Gifu/11/2005 wild type neuraminidase expressed in Sf21 insect cells after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID612398	Octanol-water distribution coefficient, log D of the compound at pH 7.4 at 100 ug/mL	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID565472	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1736917	Antiviral activity against Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) group-1 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hem	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID1813693	Protection against Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in Balb/c mouse at 4.2 uM/kg, IV administered once daily for 7 days starting from 24 hrs post viral infection	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1494260	Antiviral activity against Influenza A virus (A/Mississippi/03/01 (H1N1)) infected in MDCK cells assessed as reduction in plaque formation measured after 3 days post infection by neutral red staining-based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID300559	Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID532113	Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID542951	Inhibition of Influenza A virus (A/Saitama/78/2003(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID532115	Inhibition of human influenza A virus A/Aichi/2/1968(H3N2) neuraminidase by fluorometric method using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID542984	Inhibition of Influenza B virus (B/Shanghai/361/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID16478	Clp, plasma clearance at a dose of 50 mg/kg	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID352041	Antiviral activity against Influenza A virus (A/Singapore/1/1957 (H2N2)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID714635	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID567608	Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1181479	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1626690	Antiviral activity against Influenza A virus (A/Anhui/1/2013(H7N9)) expressing A/Puerto Rico/8/34(H1N1) genes infected in MDCK cells assessed as reduction in viral replication after 72 hrs by hemagglutination test	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID300561	Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID565275	Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID716596	Antiinflammatory activity in mouse infected with Influenza A virus (A/VietNam/1194/2004(H5N1)) NIBRG-14 assessed as reduction in IFN-gamma level in serum at 12 umol/kg/day, intranasally administered after 72 hrs by ELISA	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1490018	Inhibition of human CathA-IRES-6His-tagged NEU1 expressed in HEK293T cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID543002	Inhibition of Influenza A virus (A/duck/Memphis/546/1974(H11N9)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID523884	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID1532044	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured everyday
AID121248	Number of survivors out of 8 tested mice at 10 days after infection with influenza A/PR/8/34 (H1N1) virus	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
AID565458	Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID647177	Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Vietnam/1194/2004(H5N1))	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Synthesis and antiviral activities of novel gossypol derivatives.
AID542947	Inhibition of Influenza A virus (A/New Caledonia/20/1999(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542972	Inhibition of Influenza B virus (B/Brisbane/32/2002(Victoria) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1895908	Inhibition of Influenza A virus A/Goose/Jiangsu/1306/2014 (H5N8) neuraminidase using using 2(4-methylurnbellifery1)-a-u-acetyl neuraminic acid sodium salt hydrate (4-MUNANA) as substrate preincubated for 10 mins followed by substrate addition and measured	2021	Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24	Identification of C5-NH
AID133475	Number of virus free mice from total 10 mice infected with Influenza A/Singapore/1/57 after 12.5 mg/kg of intranasal administration for 172 hr prior to viral infection	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID515124	Inhibition of Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID488377	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
AID714640	Inhibition of Influenza B virus B/Taiwan/70641/2004 neuraminidase in virus-infected allantoic fluid using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate incubated for 10 mins prior to substrate addition by fluorescence assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID567708	Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID717174	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID147493	Inhibitory activity against influenza A neuraminidase	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
AID1813695	Protection against Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in Balb/c mouse at 84 uM/kg, IG administered once daily for 7 days starting from 24 hrs post viral infection	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID667595	Clearance in Sprague-Dawley rat at 2 mg/kg, iv	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID133477	Number of virus free mice from total 9 mice infected with Influenza A/Singapore/1/57 after 12.5 mg/kg of intranasal administration for 145 hr prior to viral infection	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1409405	Antiviral activity against Influenza A virus A/Chicken/Hebei/LZF/2014(H5N2) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID283440	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID352040	Antiviral activity against Influenza A virus (A/Yamagata/32/1989 (H1N1)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID693525	Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID717173	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1886447	Inhibition of Influenza A virus A/Goose/Guangdong/SH7/2013 (H5N1) neuraminidase using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fluorescence based microplate reader method
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID283446	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1308650	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID461109	Selectivity index, ratio of CC50 for CEF cells to EC50 for Influenza A virus (A/Korea/KBNP-0028/2000(H9N2))	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Anti-influenza diarylheptanoids from the bark of Alnus japonica.
AID1405012	Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID300558	Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID1308296	Inhibition of human Neu1 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID105771	Inhibitory concentration against Influenza A virus (A/Yamagata/32/89) MDCK cells determined by plaque reduction assay	2003	Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4	Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
AID1071483	Inhibition of neuraminidase in Influenza A virus A/Jena/5258/2009(H1N1) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID532119	Inhibition of human influenza A virus A/DK/HK/313/4/78(H5N3) neuraminidase by fluorometric method using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID542973	Inhibition of Influenza B virus (B/Malaysia/2506/2004(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1490014	Inhibition of human CathA-IRES-6His-tagged NEU1 expressed in HEK293T cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every minute for 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID1494240	Inhibition of Influenza A virus (A/chicken/Bangli/BBVD-563/2007(H5N1)) clade 2 neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID667596	Volume of distribution in Sprague-Dawley rat at 2 mg/kg, iv	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID1409409	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells after 2 days by plaque reduction assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1308308	Inhibition of Influenza A virus A/duck/Tsukuba/441/05(H11N9) neuraminidase N9 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1494257	Inhibition of Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after removal of inhibitor preincuba	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1813701	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in dog MDCK cells assessed as reduction in virus replication incubated for 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID567603	Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1731310	Antiviral activity against Influenza A virus A/Hebei Xinhua/SWL1106/2017 (H1N1) pdm09 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect preincubated for 1 hr followed by viral infection and measured after 48 hrs by crystal vi	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID1610162	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1813708	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in dog MDCK cells assessed as inhibition of viral replication preincubated for 2 hrs followed by compound wash out and viral infection and measured after 72 hrs by CCK8 ass	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1813696	Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) neuraminidase N1 using MUNANA as substrate preincubated for 30 mins followed by substrate addition by fluorescence method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1886448	Inhibition of Influenza A virus A/Goose/Jiangsu/1306/2014 (H5N8) neuraminidase using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fluorescence based microplate reader method
AID283448	Cytotoxicity against MDCK cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID567718	Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID718740	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID523885	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID567609	Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID532110	Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID515137	Fold resistance, ratio of Ki for Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase to Ki for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1241703	Cytotoxicity against MDCK cells by SRB assay	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID567616	Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1181482	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1626680	Binding affinity to zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 E119V/I222L double mutant expressed in baculovirus infected insect cells assessed as association rate constant measured up to 400 sec	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1360190	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival rate at 1.2 umol/kg/day administered intranasally for 5 days and measured at day 21 relative to control	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID1604727	Inhibition of Influenza A virus (A/Duck/Guangdong/674/2014(H5N6)) Neuraminidase N6 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 mins by fluorescence method	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
AID1308324	Antiviral activity against Influenza A virus A/duck/Tsukuba/441/05(H11N9) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID567604	Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567601	Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID539786	Inhibition of human neuraminidase 3 assessed as inhibition of GM3 hydrolysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid.
AID1604726	Inhibition of Influenza A virus (A/Chicken/Hebei/LZF/2014(H5N2)) Neuraminidase N2 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 mins by fluorescence method	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1626675	Inhibition of recombinant Influenza A virus (A/Anhui/1/2013(H7N9)) Neuraminidase N9 expressed in baculovirus infected insect cells using 4-MU-NANA as substrate preincubated for 30 mins followed by substrate addition by microplate reader analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID667585	Terminal half life in Sprague-Dawley rat at 10 mg/kg, po	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID542970	Inhibition of Influenza A virus (A/Tokushima/1/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID561141	Inhibition of Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID542980	Inhibition of Influenza B virus (B/Yamagata/398/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1409412	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID392529	Antiviral activity against influenza H3N2 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1813698	Inhibition of Influenza A virus (A/duck/Alberta/60/1976 (H12N5)) neuraminidase N5 using MUNANA as substrate preincubated for 30 mins followed by substrate addition by fluorescence method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID352049	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected mouse assessed as mouse survival at 0.3 umol/kg dosed intranasally 4 hrs before and 4 hrs, 17 hrs after viral infection measured 20 days post infection	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID567706	Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567723	Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1626704	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as bronchial wall thickening in lungs at 5 mg/kg qd administered intranasally for 7 days starting from 1 day post infection by hematoxylin and eosin	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID105808	Plaque reduction in in influenza A (A/Yamagata/32/89) was determined using plaque reduction assay (relative to Zanamivir) in MDCK cells	2003	Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4	Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
AID620578	Inhibition of influenza A virus A/PR/8/34(H1N1) neuraminidase assessed as fluorescent product using MUNANA as substrate after 60 mins by fluorescence analysis	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
AID1813697	Inhibition of Influenza A virus (A/Moscow/10/99(H3N2)) neuraminidase N2 using MUNANA as substrate preincubated for 30 mins followed by substrate addition by fluorescence method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID565254	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of compound after 1 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515132	Inhibition of Influenza B virus B/Gifu/11/2005 wild type neuraminidase expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1494258	Inhibition of Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after removal of inhibitor preincubated	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID524862	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as reduction in viral titer in lung at 0.17 mg/kg, itn administered 11 hrs post infection measured after 83 hrs post infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID392528	Antiviral activity against influenza H2N2 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID567714	Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308320	Antiviral activity against Influenza A virus A/duck/Chiba/13/06(H12N5) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1626678	Binding affinity to recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 expressed in baculovirus infected insect cells assessed as association rate constant measured up to 400 sec by surface plasmon resonance analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID722609	Inhibition of Influenza A virus (A/Indonesia/5/2005(H5N1)) neuraminidase infected in chick embryo using MUNANA as substrate after 1 hr by spectrophotometric analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID722350	Clearance in Sprague-Dawley rat at 10 mg/kg, iv	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID567600	Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567722	Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1071474	Inhibition of neuraminidase in Influenza A virus A/Rheinland-Pfalz/3911/03(H3N2) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID421013	Antiviral activity against influenza A virus A/Vietnam/1194/2004 H5N1 infected in MDCK cells after 3 days by plaque reduction assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID1181494	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID532108	Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID595829	Inhibition of viral Neuraminidase	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.
AID1729967	Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase using 4-MU-NANA as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID1408326	Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID523886	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID147346	inhibitory concentration required to inhibit neuraminidase enzyme from different strains of influenza A virus	2000	Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19	BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID1360699	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID567611	Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565267	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1485250	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID542979	Inhibition of Influenza B virus (B/Yamagata/145/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565475	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID300563	Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID352039	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID543194	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 0.3 umol/kg, itn administered 4 hrs pre-infection and at 4 hrs and 17 hrs post-infection up to 8 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542949	Inhibition of Influenza A virus (A/Yamagata/3/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565252	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G and E119G mutant infected in MDCK cells selected at 31 uM of zanamivir after 9 passage after 48 hrs by hemaggluti	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1408322	Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID203368	Inhibition of sialidase activity	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.
AID1494265	Ratio of IC50 for Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase preincubated for 60 mins followed by substrate addition measured every m	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1308297	Inhibition of human Neu4 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID716605	Antiviral activity against Influenza A virus (A/VietNam/1194/2004(H5N1)) NIBRG-14 infected in BALB/c mouse assessed as protection from virus-induced death at 12 umol/kg/day, intranasally administered bid on days 1 to 4 and day 0 of infection measured over	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID542986	Inhibition of Influenza B virus (B/Shizuoka/58/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543200	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 236 ug/kg, itn administered 4 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID525093	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival at 1.7 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID421020	Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells assessed as reduction of infectious viral titer at 100 nM incubated for 1 hr under laminar flow hood light before infection measured after 3 days	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID565469	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1626703	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as decrease in lung lesions at 20 mg/kg qd administered intranasally as single dose at 2 hrs post infection measured after 7 days post infection by hematoxylin and eosin stai	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1308294	Inhibition of human Neu3 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID147351	inhibitory concentration required to inhibit neuraminidase enzyme from different strains of influenza B virus.	2000	Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19	BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID565248	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1736921	Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID565046	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID203516	Inhibitory concentration against influenza A virus sialidase A/PR/8/34	2003	Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4	Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
AID1241704	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by SRB assay	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID1895913	Inhibition of Influenza A virus (A/California/07/2009 (H1N1)) neuraminidase H275Y mutant using 2(4-methylurnbellifery1)-a-u-acetyl neuraminic acid sodium salt hydrate (4-MUNANA) as substrate preincubated for 10 mins followed by substrate addition and meas	2021	Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24	Identification of C5-NH
AID352036	Inhibition of Influenza B virus (B/Mie/1/93) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID565479	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1813702	Antiviral activity against Influenza A virus (A/Moscow/10/99 (H3N2)) infected in dog MDCK cells assessed as reduction in virus replication incubated for 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1368742	Inhibition of Influenza A virus A/Duck/313/4/78(H5N3) sialidase preincubated for 15 mins followed by MUNA substrate addition measured after 15 mins by fluorescence assay	2018	Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1	Synthesis and anti-influenza virus evaluation of triterpene-sialic acid conjugates.
AID1532045	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay
AID712807	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1626688	Antiviral activity against Influenza A virus (A/Moscow/10/99(H3N2)) expressing A/Puerto Rico/8/34(H1N1) genes infected in MDCK cells assessed as reduction in viral replication after 72 hrs by hemagglutination test	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID567612	Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1355769	Inhibition of Influenza A virus (A/Anhui/1/2005(H5N1)) neuraminidase H274Y mutant activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID532106	Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID567617	Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542946	Inhibition of Influenza A virus (A/Yamagata/32/1989(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1736918	Antiviral activity against Influenza A virus (A/chicken/Hebei/LZF/ 2014(H5N2)) group-2 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hema	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID524845	Antimicrobial activity against Influenza B virus (B/Hong Kong/05/1972) infected in BALB/c mouse assessed as increase in mouse survival at 9.6 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID542952	Inhibition of Influenza A virus (A/Aichi/193/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1494262	Antiviral activity against Influenza A virus (A/Victoria/503/06) infected in MDCK cells assessed as reduction in plaque formation measured after 3 days post infection by neutral red staining-based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1813700	Inhibition of Influenza A virus (A/Moscow/10/99 (H3N2)) neuraminidase N2 E119V variant using MUNANA as substrate preincubated for 30 mins followed by substrate addition by fluorescence method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID561145	Inhibition of Influenza A virus (A/duck/Laos/25/2006(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID565473	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1494249	Inhibition of Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase E119V mutant activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID565474	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1409415	Inhibition of Influenza A virus A/Chicken/Hebei/LZF/2014(H5N2) neuraminidase N2 using fluorogenic MUNANA as substrate preincubated for 10 mins followed by substrate addition measured after 40 to 60 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1181483	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID283445	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1071482	Inhibition of neuraminidase in Influenza A virus A/Jena/5555/09(H1N1) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID300562	Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID1409418	Inhibition of Influenza A virus A/California/04/2009 neuraminidase N1 using fluorogenic MUNANA as substrate preincubated for 10 mins followed by substrate addition measured after 40 to 60 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID565263	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 1950 uM of zanamivir after 10 passage after 48 hrs by hemagglutinini	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1494230	Inhibition of Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID271156	Antiviral activity against avian influenza virus H5N1 measured as protective rate against MDCK cells at 50 uM by neutral red uptake assay	2006	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19	Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.
AID565266	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567587	Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID712814	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID565239	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells selected at 3,125 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565045	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID300560	Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID722351	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID565261	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 78 uM of zanamivir after 8 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID121249	Number of survivors out of 8 tested mice at 20 days after infection, with influenza A/PR/8/34 (H1N1) virus	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1889679	Inhibition of human NEU4	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID147490	Inhibitory concentration of compound against influenza viral coat protein neuraminidase; Range is 0.3-2.3 uM	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations.
AID1460742	Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) neuraminidase using MUNANA as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by fluorescence assay relative to control	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives.
AID203537	Compound was tested for its inhibitory activity against A/Victoria/3/75 (N2) sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID712808	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID565262	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 390 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565273	Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID542983	Inhibition of Influenza B virus (B/Mie/1/1993(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID523880	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID542998	Inhibition of Influenza A virus (A/duck/Alberta/60/1976(H12N5)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID352045	Antiviral activity against Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01) (H5N1)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1490016	Inhibition of human N-terminal MBP-fused NEU3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID647175	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication by plaque reduction assay	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Synthesis and antiviral activities of novel gossypol derivatives.
AID567721	Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515135	Selectivity ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID203532	Compound was tested for its inhibitory activity against A/Aichi/2/68 (N2) sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID352031	Inhibition of Influenza A virus (A/Puerto Rico/8/34(H1N1)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID524855	Antimicrobial activity against Influenza B virus (B/Malaysia/2506/2004) infected itn dosed Mustela putorius furo assessed as nasal viral titer treated after 4 hrs post infection measured after 2 days	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1308652	Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1736923	Inhibition of Influenza A virus (A/chicken/Hebei/LZF/ 2014(H5N2)) group-2 Neuraminidase N2 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 to 60 mins by fluorescence method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID1736926	Inhibition of Influenza A virus (A/Anhui/1/2005 (H5N1)) group-1 Neuraminidase N1 H274Y mutant preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 to 60 mins by fluorescence method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID460213	Antiviral activity against human influenza B virus B/TW/70325/05 in MDCK cells assessed as reduction of virus-induced cytopathic	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
AID420929	Inhibition of influenza A virus A/Vietnam/1194/2004 H5N1 neuraminidase at 10 nM using NA-STAR substrate after 15 mins incubation at room temperature by fluorescent assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID147494	Inhibitory activity against influenza B neuraminidase	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID565243	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 1950 uM of oseltamivir after 10 passage after 48 hrs by hem	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID203363	Inhibitory activity against sialidase of influenza A	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.
AID532117	Inhibition of human Influenza A virus A/PR/8/34(H1N1) neuraminidase by fluorometric method using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID1494269	Ratio of IC50 for Influenza A virus (A/chicken/Vietnam/08/2004 (H5N1)) clade 1 neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/chicken/Vietnam/08/2004 (H5N1)) clade 1 neuraminidase preincubated for 60 mins followed by substra	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID524838	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival at 4.7 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID565274	Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID543185	Ratio of IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant to IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1494251	Inhibition of Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase E119G mutant activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1494266	Ratio of IC50 for Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase H274Y mutant measured every min for 60 mins to IC50 for Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase H274Y mutant preincubated for 60 mins followed by substrate	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID717281	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID515125	Inhibition of Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID722354	Terminal half life in Sprague-Dawley rat at 10 mg/kg, po	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID567606	Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID717172	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1355768	Inhibition of Influenza A virus (A/Anhui/1/2013(H7N9)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1903186	Selectivity index, ratio of CC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability to EC50 for antiviral activity against influenza A virus H5N1 infected in dog MDCK cells assessed as reduction in inhibition of viral cytopathic ef	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).
AID1494235	Inhibition of Influenza A virus (A/swine/Shepparton/6/2009 (H1N1)) neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID532118	Inhibition of human influenza A virus A/Aichi/2/1968(H3N2) neuraminidase by fluorometric method using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID716613	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathic effect	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID542988	Inhibition of Influenza B virus (B/Yamagata/87/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID515123	Fold resistance, ratio of IC50 for Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase to IC50 for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID283447	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID693526	Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1494253	Inhibition of influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after removal of inhibitor pr	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1889677	Inhibition of human NEU2	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID421021	Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells assessed as reduction of infectious viral titer at 500 nM incubated for 1 hr under laminar flow hood light before infection measured after 3 days	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID1494237	Inhibition of Influenza A virus (A/chicken/Vietnam/08/2004 (H5N1)) clade 1 neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1857995	Inhibition of influenza virus neuraminidase	2022	Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20	Sialidase Inhibitors with Different Mechanisms.
AID234903	Relative potency against plaque formation and sialidase activity	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.
AID1626697	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as protection against lethal virus challenge by measuring body weight at 5 to 10 mg/kg qd administered intranasally for 7 days starting from 1 day po	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID543199	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 236 ug/kg, itn administered 7 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1494261	Antiviral activity against Influenza A virus (A/Fukui/45/04(H3N2)) infected in MDCK cells assessed as reduction in plaque formation measured after 3 days post infection by neutral red staining-based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID567596	Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID92326	Inhibition of plaque formation	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.
AID1610157	Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1308326	Antiviral activity against Influenza A virus (A/Narita/1/2009(H1N1)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1731307	Inhibition of Influenza A virus A/Minfang/151/2000 (H3N2) neuraminidase using MUNANA as substrate measured after 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID717171	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID543198	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 236 ug/kg, itn administered 10 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1308313	Inhibition of Influenza A virus (A/Aichi/75/2008(H3N2)) neuraminidase N2 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID560879	Inhibition of Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) neuraminidase by Michaelis-Menten equation analysis	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID567592	Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308315	Antiviral activity against Influenza A virus (A/duck/Tsukuba/67/2005(H1N1)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID636870	Inhibition of influenza A virus neuraminidase	2011	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23	The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID1485248	Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1490012	Inhibition of human N-terminal MBP-fused NEU3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every minute for 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID722611	Terminal half life in Sprague-Dawley rat at 10 mg/kg, iv	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID1308316	Antiviral activity against Influenza A virus (A/mallard/Hokkaido/24/2009(H5N1)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID92327	Inhibitory concentration by Plaque reduction assay; range- 13-27ng/mL	2002	Bioorganic & medicinal chemistry letters, Aug-05, Volume: 12, Issue:15	Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
AID565250	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 6250 nM of compound after 7 passage after 48 hrs by hemagglutininin tit	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1736922	Inhibition of Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) group-1 Neuraminidase N1 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 to 60 mins by fluorescence method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID722355	Tmax in Sprague-Dawley rat at 10 mg/kg, po	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID1408324	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID542985	Inhibition of Influenza B virus (B/Shiga/31/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1610160	Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID565055	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID542971	Inhibition of Influenza A virus (A/Saitama/07/2006(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID421012	Antiviral activity against influenza A virus A/WSN/1933 H1N1 infected in MDCK cells after 3 days by plaque reduction assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID1889676	Inhibition of human NEU1	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID92449	Antiinfluenza activity of compound against Influenza B/Harbin/7/95 in influenza cytopathic effect (CPE) assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1308322	Antiviral activity against Influenza A virus (A/duck/Tsukuba/700/2007(H7N7)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1355787	Antiviral activity against Influenza A virus A/goose/Jiangsu/1306/2014(H5N8) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1485245	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID525070	Half life in human	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID524832	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as increase in mouse survival at 14 mg/kg, itn administered for 7 days before infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1355794	Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) infected in MDCK cells assessed as reduction in plaque formation after 2 days by toluidine blue staining-based assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID460212	Antiviral activity against human influenza B virus B/TW/710/05 in MDCK cells assessed as reduction of virus-induced cytopathic	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
AID1308323	Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2006(H3N8)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1903185	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).
AID1408323	Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID515136	Selectivity ratio of IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1071481	Inhibition of neuraminidase in Influenza A virus A/HH/1580/09(H1N1) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID567704	Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1626698	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as protection against lethal virus challenge by measuring mouse survival at 5 to 10 mg/kg qd administered intranasally for 7 days starting from 1 day	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID565463	Drug level in sputum of healthy human between 6 to 24 hrs postdosing	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1360698	Cytotoxicity against MDCK cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1604725	Inhibition of Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) Neuraminidase N1 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 mins by fluorescence method	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
AID1181493	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID565272	Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1731309	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 48 hrs by crystal violet staining based assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID567591	Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543184	Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567610	Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID730333	Inhibition of inactivated Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase using MUNANA as substrate incubated for 60 mins prior to substrate addition measured after 45 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity.
AID1494271	Ratio of IC50 for Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase preincubated for 60 mins followed by substrate addition measured every min for 60 mins	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID560876	Inhibition of Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) neuraminidase by by Michaelis-Menten equation analysis	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID1355764	Inhibition of Influenza A virus (A/Chicken/Hebei/LZF/2014(H5N2)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID565249	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 1250 nM of compound after 6 passage after 48 hrs by hemagglutininin tit	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1626681	Binding affinity to zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 E119V/I222L double mutant expressed in baculovirus infected insect cells assessed as dissociation rate constant measured up to 400 se	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID761716	Inhibition of influenza A virus A/R1/5+/1957 (H2N2) N2 sialidase using fluorogenic substrate 4-methylumbelliferyl N-acetyl-alpha-D-neuraminide preincubated for 15 mins measured after 30 mins by spectrofluorometry	2013	Bioorganic & medicinal chemistry, Aug-15, Volume: 21, Issue:16	Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.
AID1813715	Protection against Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in Balb/c mouse at 8.4 uM/kg, IN administered once daily for 7 days starting from 4 hrs prior to viral infection and measured after 14 days	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1308647	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID543189	Inhibition of Influenza B virus (B/Yokohama/UT2203/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1355785	Antiviral activity against Influenza A virus A/Chicken/Hebei/LZF/2014(H5N2) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID567613	Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1895909	Inhibition of Influenza A virus A/Babol/36/2005 (H3N2) neuraminidase using using 2(4-methylurnbellifery1)-a-u-acetyl neuraminic acid sodium salt hydrate (4-MUNANA) as substrate preincubated for 10 mins followed by substrate addition and measured after 40	2021	Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24	Identification of C5-NH
AID515140	Fold resistance, ratio of Ki for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins to Ki for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID542957	Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID147504	Inhibitory activity was determined against Neuraminidase A from influenza virus A/Tokyo/3/67	2001	Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8	Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.
AID352032	Inhibition of Influenza A virus (A/Yamagata/32/1989 (H1N1)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID515133	Inhibition of Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID133474	Number of virus free mice from total 10 mice infected with Influenza A/Singapore/1/57 after 12.5 mg/kg of intranasal administration for 117 hr prior to viral infection	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1405018	Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID565244	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of zanamivir after 1 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID352034	Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID1071468	Antiviral activity against Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID713858	Inhibition of wild type Influenza A virus A/WSN/1933(H1N1) neuraminidase in virus-infected allantoic fluid using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate incubated for 10 mins prior to substrate addition by fluorescence assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID352047	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected mouse assessed as mouse survival at 0.2 umol/kg dosed intranasally 4 hrs before and 4 hrs, 17 hrs after viral infection measured 20 days post infection	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID203535	Compound was tested for its inhibitory activity against A/USSR/90/77 (N1) sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID203518	Relative potency against influenza A sialidase (A/PR/8/34) was determined using sialidase inhibitory assay (relative to Zanamivir)	2003	Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4	Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID667579	Inhibition of Influenza A virus (A/Indonesia/5/2005(H5N1)) X-31 recombinant neuraminidase using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate after 1 hr by fluorescence assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
AID1494244	Inhibition of Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1494268	Ratio of IC50 for Influenza A virus (A/swine/Shepparton/6/2009 (H1N1)) neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/swine/Shepparton/6/2009 (H1N1)) neuraminidase preincubated for 60 mins followed by substrate addition meas	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1308317	Antiviral activity against Influenza A virus (A/duck/Tsukuba/28/2005(H6N2)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID565043	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1494248	Inhibition of Influenza B virus (B/Perth/211/2001) neuraminidase D197E mutant activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1181481	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID515122	Inhibition of Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant expressed in Sf21 insect cells after 60 mins by MUNANA based assay	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID532114	Inhibition of human Influenza A virus A/PR/8/34(H1N1) neuraminidase by fluorometric method using 4MU-NeuAc substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID1308300	Inhibition of Influenza A virus (A/mallard/Hokkaido/24/2009(H5N1)) neuraminidase N1 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID542953	Inhibition of Influenza A virus (A/Okinawa/42/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1308310	Inhibition of Influenza A virus (A/Narita/1/2009(H1N1)) neuraminidase N1 V149I mutant activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1071475	Inhibition of neuraminidase in Influenza A virus A/Berlin/10/04(H3N2) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID543004	Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565049	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID560877	Inhibition of Influenza A virus (A/Turkey/651242/2006(H5N1)) neuraminidase by Michaelis-Menten equation analysis	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID567597	Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1886450	Inhibition of Influenza A virus A/California/04/2009 (H1N1) Neuraminidase H274Y mutant using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fluorescence based microplate reader method
AID1895914	Inhibition of Influenza A virus A/Anhui/1/2005 (H5N1) Neuraminidase H274Y mutant using 2(4-methylurnbellifery1)-a-u-acetyl neuraminic acid sodium salt hydrate (4-MUNANA) as substrate preincubated for 10 mins followed by substrate addition and measured aft	2021	Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24	Identification of C5-NH
AID722610	Inhibition of Influenza A virus (A/Sydney/5/1997(H3N2)) neuraminidase infected in chick embryo using MUNANA as substrate after 1 hr by spectrophotometric analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID1610158	Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID420936	Inhibition of influenza A virus A/Vietnam/1194/2004 H5N1 neuraminidase using NA-STAR substrate after 15 mins incubation at room temperature by fluorescent assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID420928	Inhibition of influenza A virus A/WSN/1933 H1N1 neuraminidase at 40 nM using NA-STAR substrate after 15 mins incubation at room temperature by fluorescent assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID1360171	Inhibition of Influenza A virus (A/WSN/1933(H1N1)) neuraminidase H275Y mutant using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured for 15 mins by fluorescence assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID1409406	Antiviral activity against Influenza A virus A/duck/Guangdong/674/2014(H5N6) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1626691	Antiviral activity against A/Puerto Rico/8/34(H1N1) genes expressing anamivir/oseltamivir resistant Influenza A virus (A/Shanghai/2/2013(H7N9)) harboring Neuraminidase N9 R294K mutant infected in MDCK cells assessed as reduction in viral replication after	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1626705	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as bronchial wall thickening in lungs at 20 mg/kg qd administered intranasally as single dose at 2 hrs post infection measured after 7 days post infe	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID565245	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565258	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID693527	Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID567713	Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1))virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308318	Antiviral activity against Influenza A virus (A/duck/Tsukuba/394/2005(H5N3)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID567716	Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1729978	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells as reduction in plaque formation	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID1813705	Antiviral activity against Influenza A virus (A/Moscow/10/99 (H3N2)) harboring NA E119V mutant infected in dog MDCK cells assessed as reduction in virus replication incubated for 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID712796	Cytotoxicity against dog MDCK cells assessed as cell morphology alterations	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID565471	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1408327	Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID542948	Inhibition of Influenza A virus (A/Shiga/1/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID460211	Antiviral activity against human influenza A virus A/TW/3446/04 (H3N2) in MDCK cells assessed as reduction of virus-induced cytopathic effect	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
AID567595	Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542987	Inhibition of Influenza B virus (B/Yamagata/85/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID543201	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 236 ug/kg, itn administered 1 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1494256	Inhibition of Influenza A virus (A/chicken/Bangli/BBVD-563/2007(H5N1)) clade 2 neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after remov	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1308319	Antiviral activity against Influenza A virus (A/duck/Tsukuba/20/2007(H8N4)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1071480	Antiviral activity against Influenza A virus H1N1	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID1308311	Inhibition of Influenza A virus A/Yamaguchi/20/06(H1N1) neuraminidase N1 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1532043	Inhibition of Clostridium neuraminidase preincubated for 2 mins followed by neuraminidase fluorescent addition and measured after 30 mins by fluorescence assay
AID1494241	Inhibition of Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1071477	Inhibition of neuraminidase H274Y mutant in Oseltamivir-resistant Influenza A virus A/Berlin/55/08(H1N1) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID1355786	Antiviral activity against Influenza A virus A/duck/Guangdong/674/2014(H5N6) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1626707	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as immune cell infiltration in lungs at 20 mg/kg qd administered intranasally as single dose at 2 hrs post infection measured after 7 days post infec	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1241697	Inhibition of recombinant Influenza A virus H1N1 neuraminidase	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID1129834	Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate after 30 mins	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
AID352042	Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) assessed viral plaque reduction	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID523887	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID542975	Inhibition of Influenza B virus (B/Shiga/17/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID140430	Compound was tested for in vivo efficacy in mouse model of influenza A virus A/Singapore/1/57 at dose of 50 mg/kg (ip)	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID567590	Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID560871	Inhibition of Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) neuraminidase by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID1494243	Inhibition of Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1360697	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID473065	Inhibition of human neuraminidase 2	2010	Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7	Complexity in influenza virus targeted drug design: interaction with human sialidases.
AID1331612	Competitive inhibition of MDCK infected Influenza A virus A/WSN/33(H1N1) neuraminidase using MU-NANA as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by spectrofluorometric method	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
AID1895907	Inhibition of Influenza A virus A/Goose/Guangdong/SH7/2013 (H5N1) neuraminidase using 2(4-methylurnbellifery1)-a-u-acetyl neuraminic acid sodium salt hydrate (4-MUNANA) as substrate preincubated for 10 mins followed by substrate addition and measured afte	2021	Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24	Identification of C5-NH
AID1494239	Inhibition of Influenza A virus (A/chicken/Bangli/BBVD-563/2007(H5N1)) clade 2 neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID140427	Compound was tested for in vivo efficacy in mouse model of influenza A virus A/Singapore/1/57 at dose of 0.5 mg/kg (in)	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1409416	Inhibition of Influenza A virus A/goose/Jiangsu/1306/2014(H5N8) neuraminidase N8 using fluorogenic MUNANA as substrate preincubated for 10 mins followed by substrate addition measured after 40 to 60 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID714639	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933/H275Y(H1N1) neuraminidase in virus-infected allantoic fluid using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate incubated for 10 mins prior to substrate addition by	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID488379	Inhibition of Influenza A virus neuraminidase	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
AID567717	Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1355763	Inhibition of Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1181480	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID565242	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 390 uM of oseltamivir after 9 passage after 48 hrs by hemag	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565468	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID542982	Inhibition of Influenza B virus (B/Saitama/01/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1490017	Inhibition of human N-terminal MBP-fused NEU2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID565462	Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567719	Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308651	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1308309	Inhibition of Influenza A virus (A/California/04/2009(H1N1)) neuraminidase N1 V149I mutant activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID565268	Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID420935	Inhibition of influenza A virus A/WSN/1933 H1N1 neuraminidase using NA-STAR substrate after 15 mins incubation at room temperature by fluorescent assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID542960	Inhibition of Influenza A virus (A/Wellington/1/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542992	Inhibition of Influenza B virus (B/Tokushima/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1626682	Binding affinity to recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 expressed in baculovirus infected insect cells measured up to 400 sec by surface plasmon resonance analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID524861	Antimicrobial activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as reduction in viral titer in lung at 0.17 mg/kg, itn administered 11 hrs post infection measured after 59 hrs post infection	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1355770	Inhibition of Influenza A virus (A/Babol/36/2005(H3N2)) neuraminidase E119V mutant activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1360174	Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferation assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID565247	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID352035	Inhibition of Influenza A virus (A/Kitakyushu/159/93(H3N2)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID565255	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1308328	Antiviral activity against Influenza A virus A/Kitakyushu/10/06(H1N1) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID542997	Inhibition of Influenza A virus (A/turkey/Ontario/6,118/1968(H8N4)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID283444	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID712809	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID542955	Inhibition of Influenza A virus (A/Yamagata/83/2006(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID523881	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID567605	Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565042	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID612401	Antiviral activity against influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	2011	Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16	Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
AID1494264	Antiviral activity against Influenza B virus (B/Perth/211/2001) infected in MDCK cells assessed as reduction in plaque formation measured after 3 days post infection by neutral red staining-based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1494267	Ratio of IC50 for Influenza A virus (A/California/07/09 (H1N1)) neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/California/07/09 (H1N1)) neuraminidase preincubated for 60 mins followed by substrate addition measured every min	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1736925	Inhibition of Influenza A virus (A/goose/Jiangsu/1306/2014 (H5N8)) group-1 Neuraminidase N8 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 to 60 mins by fluorescence method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID543006	Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1604728	Inhibition of Influenza A virus H5N1 Neuraminidase N1 H274Y mutant preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 mins by fluorescence method	2020	European journal of medicinal chemistry, Feb-01, Volume: 187	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.
AID203546	Compound was tested for its inhibitory activity against B/Lee/40 sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1360173	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells expressing neuraminidase H275Y mutant assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter96 aqueous non-radioactive cell proliferat	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1626689	Antiviral activity against A/Puerto Rico/8/34(H1N1) genes expressing anamivir/oseltamivir resistant Influenza A virus (A/Moscow/10/99(H3N2)) harboring Neuraminidase N2 E119V/I222L double mutant infected in MDCK cells assessed as reduction in viral replica	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID542974	Inhibition of Influenza B virus (B/Ohio/01/2005(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567712	Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1494275	Ratio of IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase measured every min for 60 mins to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase preincubated for 60 mins followed by substrate addition measured every min for 60 mins	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID384920	Inhibition of influenza virus neuraminidase	2008	European journal of medicinal chemistry, Mar, Volume: 43, Issue:3	QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
AID748614	Inhibition of human NEU2 using 4MU-NeuAc as substrate after 15 to 30 mins by fluorimetric analysis	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.
AID1405011	Selectivity index, ratio of IC50 for MBP-fused recombinant human neuraminidase 4 to IC50 for MBP-fused recombinant human neuraminidase 2	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID543195	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 0.3 umol/kg, itn administered 4 hrs pre-infection and at 4 hrs and 17 hrs post-infection up to 10 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID306105	Inhibition of sialidase in Human parainfluenza virus 3 C243	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	Synthesis and evaluation of 4-O-alkylated 2-deoxy-2,3-didehydro-N-acetylneuraminic acid derivatives as inhibitors of human parainfluenza virus type-3 sialidase activity.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524854	Antimicrobial activity against Influenza B virus (B/Malaysia/2506/2004) infected itn dosed Mustela putorius furo assessed as nasal viral titer treated after 4 hrs post infection measured after 1 day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1241698	Inhibition of recombinant Influenza A virus H5N1 neuraminidase	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID565465	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565238	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1071476	Inhibition of neuraminidase in Influenza A virus A/Hong Kong/68(H3N2) using Na-star as substrate preincubated for 10 to 30 mins followed by substrate addition measured after 10 to 30 mins by chemiluminescence-based assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID532111	Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID1494259	Inhibition of Influenza B virus (B/Perth/211/2001) neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after removal of inhibitor preincubated	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1405019	Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID722349	Volume of distribution at steady state in Sprague-Dawley rat at 10 mg/kg, iv	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID420930	Inhibition of influenza A virus A/Vietnam/1194/2004 H5N1 neuraminidase at 40 nM using NA-STAR substrate after 15 mins incubation at room temperature by fluorescent assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID515128	Selectivity ratio of IC50 for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1736920	Antiviral activity against Influenza A virus (A/goose/Jiangsu/1306/2014 (H5N8)) group-1 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hem	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID1494273	Ratio of IC50 for Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase preincubated for 60 mins followed by substrate addition measured every min for 60 mins	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID523883	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID543005	Ratio of IC50 for Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID730331	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity.
AID1886446	Inhibition of Influenza A virus A/PR/8/1934 (H1N1) neuraminidase using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fluorescence based microplate reader method
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID542995	Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01)(H5H1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1405015	Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1903202	Antiviral activity against Influenza B virus (B/Lee/1940) H1N1 infected in dog MDCK cells assessed as inhibition of viral cytopathic effect incubated for 48 hrs by CCK-8 assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp).
AID203667	Compound was tested for its inhibitory activity against B/Victoria/102/85 (N2) sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1308329	Antiviral activity against Influenza A virus (A/Aichi/75/2008(H3N2)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID567728	Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID523882	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID1736924	Inhibition of Influenza A virus (A/Duck/Guangdong/674/2014 (H5N6)) group-2 Neuraminidase N6 preincubated for 10 mins followed by MUNANA substrate addition and measured after 40 to 60 mins by fluorescence method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID1626674	Inhibition of zanamivir/oseltamivir resistant recombinant Influenza A virus (A/Moscow/10/99(H3N2)) Neuraminidase N2 E119V/I222L double mutant expressed in baculovirus infected insect cells using 4-MU-NANA as substrate preincubated for 30 mins followed by	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1494274	Ratio of IC50 for Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase E119G mutant measured every min for 60 mins to IC50 for Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase E119G mutant preincubated for 60 mins followed by substrate addition measured e	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1355761	Inhibition of Influenza A virus (A/California/04/2009(H1N1)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1626700	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as protection against lethal virus challenge by measuring mouse survival at 20 mg/kg administered intranasally as single dose at 2 hrs post infection	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1308303	Inhibition of Influenza A virus (A/duck/Tsukuba/20/2007(H8N4)) neuraminidase N4 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1409407	Antiviral activity against Influenza A virus A/goose/Jiangsu/1306/2014(H5N8) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1308299	Inhibition of Influenza A virus (A/duck/Tsukuba/67/2005(H1N1)) neuraminidase N1 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID543204	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 166 ug/kg, itn administered 4 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID147312	Fold resistance of E119G to compound against neuraminidase in a MUNANA-based enzyme inhibition assay, expressed as the ratio of IC50 of comp. with variant N9 to that of with wild-type N9	2002	Journal of medicinal chemistry, May-23, Volume: 45, Issue:11	Structural studies of the resistance of influenza virus neuramindase to inhibitors.
AID1355762	Inhibition of Influenza A virus (A/Babol/36/2005(H3N2)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID542954	Inhibition of Influenza A virus (A/Aichi/169/2005(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1729970	Inhibition of Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) neuraminidase using 4-MU-NANA as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID716614	Inhibition of Influenza A virus A/WSN/1933(H1N1)) neuraminidase in the presence of 2'-(4-methyl-umbelliferyl)-alphaD-N-acetylneuraminic acid substrate after 10 mins by fluorometric assay	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID542999	Inhibition of Influenza A virus (A/duck/England/1/1956(H11N6)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542959	Inhibition of Influenza A virus (A/Wyoming/03/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID560872	Inhibition of Influenza A virus (A/Turkey/651242/2006(H5N1)) neuraminidase by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID1308295	Inhibition of human Neu2 expressed in HEK293T cells using 4MU-Neu5Ac as substrate incubated for 30 mins by HPLC analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID542965	Inhibition of Influenza A virus (A/Shiga/5/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542950	Inhibition of Influenza A virus (A/Yamagata/57/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID722600	Cmax in Sprague-Dawley rat at 10 mg/kg, po	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
AID567598	Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308305	Inhibition of Influenza A virus (A/duck/Shiga/8/2004(H4N6)) neuraminidase N6 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID515134	Fold resistance, ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1626709	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as respiratory epithelium desquamation at 20 mg/kg qd administered intranasally as single dose at 2 hrs post infection measured after 7 days post inf	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1308643	Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1729969	Inhibition of Influenza A virus (A/Babol/36/2005 (H3N2)) neuraminidase using 4-MU-NANA as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID515139	Fold resistance, ratio of Ki for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to Ki for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1626706	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Balb/c mouse assessed as immune cell infiltration in lungs at 5 mg/kg qd administered intranasally for 7 days starting from 1 day post infection by hematoxylin and eosin s	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID716598	Cytotoxicity against MDCK cells at 100 uM	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Enhanced anti-influenza agents conjugated with anti-inflammatory activity.
AID1152624	Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Vietnam/1194/2004(H5N1))	2014	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12	Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H(5)N(1).
AID543186	Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567602	Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1494242	Inhibition of Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID525083	Antimicrobial activity against Influenza B virus (B/Hong Kong/05/1972) infected in BALB/c mouse assessed as increase in mouse survival at 1.1 mg/kg, itn administered for 7 days before infection measured at day 20	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
AID1729980	Cytotoxicity against MDCK cells assessed as reduction in cell viability by MTT assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID1494250	Inhibition of Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase E119V mutant activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1408325	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1181485	Cytotoxicity against MDCK cells assessed as change in cell morphology after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID488375	Inhibition of Influenza A virus A/WSN/1933(H1N1) neuraminidase	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
AID714644	Inhibition of Influenza A virus (A/reassortant/NIBRG-14(Viet Nam/1194/2004 x Puerto Rico/8/1934)(H5N1)) neuraminidase in virus-infected allantoic fluid using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate incubated for 10 mins prio	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID565240	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M mutant infected in MDCK cells selected at 16 uM of oseltamivir after 7 passage after 48 hrs by hemagglutininin	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID543187	Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1409417	Inhibition of Influenza A virus A/Anhui/1/2005(H5N1) neuraminidase N1 H274Y mutant using fluorogenic MUNANA as substrate preincubated for 10 mins followed by substrate addition measured after 40 to 60 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID92334	Antiinfluenza activity of compound against Influenza A/Sydney/5/97 in influenza cytopathic effect (CPE) assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID565467	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1064128	Inhibition of Influenza A virus A/Hong Kong/8/1968 (H3N2) neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Bifunctional thiosialosides inhibit influenza virus.
AID1626692	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTT assay	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID647176	Cytotoxicity against MDCK cells by MTT assay	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Synthesis and antiviral activities of novel gossypol derivatives.
AID1889674	Inhibition of NEU2 (unknown origin) using Neu5Acalpha2-3GalbetapNP as substrate incubated for 30 mins	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID565241	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 78 uM of oseltamivir after 8 passage after 48 hrs by hemagg	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID542996	Inhibition of Influenza A virus (A/duck/Hokkaido/84/2002(H5N3)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1308314	Inhibition of Influenza A virus (A/Aichi/102/2008(H3N2)) neuraminidase N2 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID532112	Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using ganglioside GM3 substrate	2008	Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10	Limited inhibitory effects of oseltamivir and zanamivir on human sialidases.
AID1064127	Inhibition of Influenza A virus A/California/07/2009 (H1N1) neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Bifunctional thiosialosides inhibit influenza virus.
AID1886451	Inhibition of Influenza A virus A/Anhui/1/2005 (H5N1) Neuraminidase H274Y mutant using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fluorescence based microplate reader method
AID714636	Inhibition of Influenza A virus A/Udorn/1972(H3N2) neuraminidase in virus-infected allantoic fluid using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate incubated for 10 mins prior to substrate addition by fluorescence assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID717169	Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1308330	Antiviral activity against Influenza A virus (A/Aichi/102/2008(H3N2)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1360696	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1405013	Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID567710	Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308321	Antiviral activity against Influenza A virus (A/duck/Shiga/8/2004(H4N6)) infected in MDCK cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID565257	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1886449	Inhibition of Influenza A virus A/Aichi/2/1968 (H3N2) neuraminidase using MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 mins by fluorescence based microplate reader method
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1813707	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in dog MDCK cells assessed as inhibition of viral replication preincubated for 2 hrs followed by viral infection and measured after 72 hrs by CCK8 assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID1409413	Inhibition of Influenza A virus A/duck/Guangdong/674/2014(H5N6) neuraminidase N6 using fluorogenic MUNANA as substrate preincubated for 10 mins followed by substrate addition measured after 40 to 60 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID543190	Inhibition of Influenza B virus (B/Yokohama/UT3318/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1204714	Total plasma concentration in CD1 mouse at 30 mg/kg, po measured at 20 mins by reversed-phase UPLC/MS analysis	2015	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12	Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
AID567599	Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID543188	Ratio of IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant to IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1064130	Antiviral activity against Influenza A virus A/Hong Kong/8/1968 (H3N2) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Bifunctional thiosialosides inhibit influenza virus.
AID543191	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 66 ug/kg, itn administered 4 hrs pre-infection and at 4 hrs and 18 hrs post-infection up to 10 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565054	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID314411	Inhibition of influenza A/N1/PR/8/34 neuraminidase	2008	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5	Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.
AID543182	Ratio of IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant to IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID717170	Cytotoxicity against dog MDCK cells assessed as cell morphology alterations by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1152622	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 2 to 3 days by crystal violet staining-based plaque reduction assay	2014	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12	Design, synthesis and biological evaluation of small molecular polyphenols as entry inhibitors against H(5)N(1).
AID542956	Inhibition of Influenza A virus (A/Singapore/1/1957(H2N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID542969	Inhibition of Influenza A virus (A/Osaka/56/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID515131	Fold resistance, ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1308302	Inhibition of Influenza A virus (A/duck/Tsukuba/394/2005(H5N3)) neuraminidase N3 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID567614	Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542958	Inhibition of Influenza A virus (A/Kitakyushu/159/1993(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID567725	Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1494247	Inhibition of Influenza B virus (B/Perth/211/2001) neuraminidase D197E mutant activity using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1308306	Inhibition of Influenza A virus (A/duck/Tsukuba/700/2007(H7N7)) neuraminidase N7 activity using 4MU-Neu5Ac as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by fluorescence analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID203373	Inhibitory activity against influenza B sialidase (Victoria)	2001	Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5	Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.
AID1729979	Antiviral activity against Influenza A virus (A/WSN/67/05(H3N2)) infected in MDCK cells as reduction in plaque formation	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID352038	Inhibition of Tamiflu-resistant Influenza A virus (A/Yokohama/67/2006 (H1N1)) sialidase	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
AID343686	Inhibition of influenza virus neuraminidase	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.
AID1064129	Antiviral activity against Influenza A virus A/California/07/2009 (H1N1) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Bifunctional thiosialosides inhibit influenza virus.
AID567615	Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1409410	Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) infected in MDCK cells after 2 days by plaque reduction assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1071470	Antiviral activity against Influenza A virus A/Jena/5258/2009(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
AID1308325	Antiviral activity against Influenza A virus (A/California/04/2009(H1N1)) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID712816	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID515138	Fold resistance, ratio of Ki for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins to Ki for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins	2010	Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17	Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID567707	Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543003	Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1308645	Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1731308	Inhibition of Influenza B virus B/Sichuan/01/96 neuraminidase using MUNANA as substrate measured after 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
AID1241701	Competitive inhibition of recombinant Influenza A virus H1N1 neuraminidase using MU-NANA as substrate	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID565251	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 31 uM of compound after 8 passage after 48 hrs by hemagglutininin titer	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1409404	Antiviral activity against Influenza A virus A/goose/Guangdong/SH7/2013(H5N1) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID567593	Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID542981	Inhibition of Influenza B virus (B/Aichi/3/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID314410	Inhibition of influenza B/Memphis/3/89 neuraminidase	2008	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5	Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.
AID1405010	Selectivity index, ratio of IC50 for MBP-fused recombinant human neuraminidase 4 to IC50 for MBP-fused recombinant human neuraminidase 3	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1494234	Inhibition of Influenza A virus (A/California/07/09 (H1N1)) neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID565264	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1626696	Half life in Sprague-Dawley rat at 6 umol/kg, iv by HPLC analysis	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
AID1494252	Inhibition of Influenza A virus (A/NWS/G70C(H1N9)) neuraminidase E119G mutant activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID461108	Antiviral activity against Influenza A virus (A/Korea/KBNP-0028/2000(H9N2)) infected in chicken egg after 5 days by hemagglutinination assay	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Anti-influenza diarylheptanoids from the bark of Alnus japonica.
AID718739	Toxicity in MDCK cells assessed as induction of cell morphology changes	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID1241705	Therapeutic index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus H1N1	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID1494229	Inhibition of Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase activity using 4-MUNANA as substrate preincubated for 60 mins followed by substrate addition measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID704187	Inhibition of Influenza A virus sialidase N2	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Exploring the interactions of unsaturated glucuronides with influenza virus sialidase.
AID420927	Inhibition of influenza A virus A/WSN/1933 H1N1 neuraminidase at 10 nM using NA-STAR substrate after 15 mins incubation at room temperature by fluorescent assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
AID565271	Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID560875	Inhibition of Influenza A virus (A/duck/Laos/25/2006(H5N1)) neuraminidase by fluorometric assay	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID133478	Number of virus free mice from total 9 mice infected with Influenza A/Singapore/1/57 after 12.5 mg/kg of intranasal administration for 51 hr prior to viral infection	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
AID1494263	Antiviral activity against Influenza A virus (A/NWS/G70C(H1N9)) infected in MDCK cells assessed as reduction in plaque formation measured after 3 days post infection by neutral red staining-based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID714642	Inhibition of Influenza A virus A/Taiwan/3446/2002(H3N2) neuraminidase in virus-infected allantoic fluid using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid as substrate incubated for 10 mins prior to substrate addition by fluorescence assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID1308327	Antiviral activity against Influenza A virus A/Yamaguchi/20/06(H1N1) infected in dog AX4 cells preincubated for 1 hr followed by infection measured after 19 to 20 hrs by galactosidase-based fluorescence assay and peroxidase-based chromogenic assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID1241699	Inhibition of recombinant Influenza A virus H3N2 neuraminidase	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID542966	Inhibition of Influenza A virus (A/Yamagata/1/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID560878	Inhibition of Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) neuraminidase by Michaelis-Menten equation analysis	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
AID203545	Compound was tested for its inhibitory activity against B/Beijing/1/87 (N2) sialidases.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1485251	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1494270	Ratio of IC50 for Influenza A virus (A/chicken/Bangli/BBVD-563/2007(H5N1)) clade 2 neuraminidase measured every min for 60 mins to IC50 for Influenza A virus (A/chicken/Bangli/BBVD-563/2007(H5N1)) clade 2 neuraminidase preincubated for 60 mins followed by	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1405017	Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis	2018	Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19	Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID565253	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 781 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin ti	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID542990	Inhibition of Influenza B virus (B/Saitama/01/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1494255	Inhibition of Influenza A virus (A/chicken/Vietnam/08/2004 (H5N1)) clade 1 neuraminidase activity using 4-MUNANA as substrate assessed as reactivation half life by measuring reaction rate to reach 50% of maximum rate of uninhibited control after removal o	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID542967	Inhibition of Influenza A virus (A/Yamagata/2/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1204717	Total plasma concentration in CD1 mouse at 30 mg/kg, po measured at 60 mins by reversed-phase UPLC/MS analysis	2015	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12	Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.
AID542963	Inhibition of Influenza A virus (A/Hiroshima/52/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1610155	Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID567727	Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1129833	Inhibition of Influenza A virus (A/RI/5+/1957(H2N2)) recombinant neuraminidase using MUNANA as substrate at 100 uM after 30 mins	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
AID1408328	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID542994	Inhibition of Influenza B virus (B/Yamagata/113/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID565052	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID461110	Cytotoxicity against CEF cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Anti-influenza diarylheptanoids from the bark of Alnus japonica.
AID567702	Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme expressing wild type enzyme by NA-star substrate based chemi	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID543183	Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1308298	Inhibition of human Neu4 expressed in HEK293T cells using GM3 as substrate incubated for 30 mins by HPLC analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
AID203357	Compound was tested for inhibitory concentration against Influenza sialidase type A	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
AID1490013	Inhibition of human N-terminal MBP-fused NEU2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every minute for 30 mins by fluorescence based assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Selective Inhibitors of Human Neuraminidase 3.
AID1308648	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1241707	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced change in cell morphology at 10 ug/ml after 2 days by microscopic analysis	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Anti-influenza activities of polyphenols from the medicinal mushroom Phellinus baumii.
AID1355793	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in plaque formation after 2 days by toluidine blue staining-based assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID565270	Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1064131	Inhibition of Influenza A virus H3N2 neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs	2014	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2	Bifunctional thiosialosides inhibit influenza virus.
AID712810	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1308649	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1308644	Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID565459	Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1494231	Inhibition of Influenza A virus (A/Mississippi/03/01 (H1N1)) neuraminidase H274Y mutant using 4-MUNANA as substrate measured every min for 60 mins by fluorescence assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID543203	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in mouse infection model at 166 ug/kg, itn administered 7 days pre-infection up to 20 days	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID1729972	Inhibition of Influenza A virus (A/Anhui/1/2005(H5N1)) neuraminidase H274Y mutant using 4-MU-NANA as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
AID542978	Inhibition of Influenza B virus (B/Tokushima/1/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1494272	Ratio of IC50 for Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase E119V mutant measured every min for 60 mins to IC50 for Influenza A virus (A/Fukui/45/04(H3N2)) neuraminidase E119V mutant preincubated for 60 mins followed by substrate addition meas	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.
AID1355767	Inhibition of Influenza A virus (A/chicken/china/415/2013(H9N2)) neuraminidase activity using 4-MUNANA as substrate preincubated for 10 mins followed by substrate addition and measured after 40 to 60 mins by chemiluminescence assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1408333	Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1408329	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1610161	Cytotoxicity against dog MDCK cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID714634	Terminal half life in Sprague-Dawley rat at 10 mg/kg, po	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Development of oseltamivir phosphonate congeners as anti-influenza agents.
AID693524	Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1795717	Neuraminidase Inhibition Assay from Article 10.1021/jm970374b: \\Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
AID1802683	Sialidase Assay from Article 10.1186/1471-2091-13-19: \\Optimization of a direct spectrophotometric method to investigate the kinetics and inhibition of sialidases.\\	2012	BMC biochemistry, Oct-02, Volume: 13	Optimization of a direct spectrophotometric method to investigate the kinetics and inhibition of sialidases.
AID1795726	Neuraminidase Inhibition Assay from Article 10.1021/jm010277p: \\Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.\\	2001	Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25	Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	1998	Structure (London, England : 1993), Jun-15, Volume: 6, Issue:6	Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.
AID1811	Experimentally measured binding affinity data derived from PDB	1998	Structure (London, England : 1993), Jun-15, Volume: 6, Issue:6	Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
AID1811	Experimentally measured binding affinity data derived from PDB	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	113 (9.97)	18.2507
2000's	397 (35.04)	29.6817
2010's	537 (47.40)	24.3611
2020's	86 (7.59)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	85 (7.28%)	5.53%
Reviews	215 (18.41%)	6.00%
Case Studies	57 (4.88%)	4.05%
Observational	7 (0.60%)	0.25%
Other	804 (68.84%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) With Moxifloxacin as a Positive Control in Healthy Volunteers [NCT01353729]	Phase 1	40 participants (Actual)	Interventional	2011-05-19	Completed
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes [NCT04867707]	Phase 2	14 participants (Actual)	Interventional	2021-07-14	Active, not recruiting
A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteer [NCT00980109]	Phase 4	390 participants (Actual)	Interventional	2009-09-30	Completed
An Open-label, Multi-center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects With Confirmed Influenza Infection [NCT01014988]	Phase 2	202 participants (Actual)	Interventional	2009-11-30	Completed
Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection [NCT00830323]	Phase 2	60 participants (Anticipated)	Interventional	2009-01-31	Terminated
A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir After Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults [NCT02377401]	Phase 1	24 participants (Actual)	Interventional	2015-04-28	Completed
Multicentre, Randomized, Controlled Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As The First Line Treatment For Human Swine Influenza (H1N1) Infection In Designated Flu Clinics During The Pandemic Influenza in Hong Kong [NCT00979667]	Phase 3	4 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to Decreased Influenza activity; thus decrease/no eligible patient to recruit)
A Pilot Study for a Randomized Controlled Trial to Compare Trivalent Split Virus Influenza Vaccine to Seasonal Antiviral Prophylaxis in Healthcare and Other Healthy Adults: Assessment of Zanamivir Versus Vaccine (Stop-Flu-2) [NCT00784784]	Phase 3	64 participants (Actual)	Interventional	2008-11-30	Completed
Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects [NCT00921726]	Phase 1	17 participants (Actual)	Interventional	2009-07-31	Completed
Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B [NCT02014649]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2013-11-30	Terminated(stopped due to Study was terminated as per BARDA decision to terminate contract.)
A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects [NCT00989404]	Phase 1	18 participants (Actual)	Interventional	2009-10-12	Completed
Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study [NCT00799760]	Phase 3	541 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to Just Terminated for the end of the pandemia)
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults [NCT01231620]	Phase 3	626 participants (Actual)	Interventional	2011-01-15	Completed
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis) [NCT01390792]		622 participants (Actual)	Observational	2007-01-31	Completed
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA) [NCT05648448]	Phase 2	250 participants (Anticipated)	Interventional	2023-02-22	Recruiting
Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects [NCT00540501]	Phase 1	0 participants (Actual)	Interventional	2007-10-31	Withdrawn(stopped due to Contract agreement not reached)
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial [NCT04597437]	Early Phase 1	74 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients [NCT00867139]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2009-03-31	Completed
An Open-label, Multi-centre, Single Arm Study to Evaluate the Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Confirmed Influenza Infection (NAI115215) [NCT01527110]	Phase 3	21 participants (Actual)	Interventional	2012-01-01	Completed
Collection of Patients' Background InformationRelenza® Sentinel Site Monitoring Program in Japan [NCT01199744]		1,575 participants (Actual)	Observational	2009-11-30	Completed
Assessing the Safety of Inhaled Zanamivir Exposure in Pregnant Women [NCT01462487]		1 participants (Actual)	Observational	2011-07-31	Completed
Prophylactic Efficacy of Relenza Against Influenza A and B [NCT01156701]		171,705 participants (Actual)	Observational	2009-07-31	Completed
Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China [NCT01459081]	Phase 3	298 participants (Actual)	Interventional	2011-10-31	Completed
A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection [NCT01793883]	Phase 2	639 participants (Actual)	Interventional	2013-05-31	Completed
An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Comp [NCT04494412]	Phase 2	12 participants (Anticipated)	Interventional	2022-11-21	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00784784 (2) [back to overview]	Number of Subjects Adhering to Long-term Zanamivir Prophylaxis
NCT00784784 (2) [back to overview]	Number of Laboratory Confirmed Influenza Infections
NCT00867139 (12) [back to overview]	Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption
NCT00867139 (12) [back to overview]	Days on Supplemental Oxygen
NCT00867139 (12) [back to overview]	Duration of Hospitalization
NCT00867139 (12) [back to overview]	Duration of Symptoms
NCT00867139 (12) [back to overview]	Frequency of Confirmed Pneumonia
NCT00867139 (12) [back to overview]	Number of Deaths
NCT00867139 (12) [back to overview]	Number of Participants With ICU Admissions
NCT00867139 (12) [back to overview]	Number of Participants With Intubations
NCT00867139 (12) [back to overview]	Number of Participants With Viral Load Decrease as a Function of Time
NCT00867139 (12) [back to overview]	Number of Participants With Viral Resistance as a Function of Drug Exposure
NCT00867139 (12) [back to overview]	Pharmacokinetics (AUC0-last) of TCAD
NCT00867139 (12) [back to overview]	Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1
NCT01014988 (33) [back to overview]	Geometric Mean Terminal Half Life (t1/2) of Zanamivir
NCT01014988 (33) [back to overview]	Geometric Mean Volume of Distribution (Vd) of Zanamivir
NCT01014988 (33) [back to overview]	Mean Viral Susceptibility to Zanamivir at Baseline (Day 1) and All Post-Baseline Visits Collectively
NCT01014988 (33) [back to overview]	Median Body Temperature at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Median Time to Clinical Response (Sustained Resolution) of All Vital Signs (Composite)
NCT01014988 (33) [back to overview]	Median Corrected QT Interval (QTc) for Heart Rate by Fridericia's Formula (QTcF) and Bazett's Formula (QTcB) at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Median Duration of Hospitalization and Intensive Care Unit (ICU) Stays
NCT01014988 (33) [back to overview]	Median Heart Rate at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Median Oxygen Saturation Measured Via Transcutaneous Oximetry (TCPO2) at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Median Respiration Rate at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Median Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Number of Participants Assessed as Normal/Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at Baseline (Day 1)
NCT01014988 (33) [back to overview]	Number of Participants With the Indicated Clinical Chemistry Values Relative to the Normal Range at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Number of Participants With the Indicated Hematology Values Relative to the Normal Range at Baseline (Day 1) and Day 5
NCT01014988 (33) [back to overview]	Number of Participants With the Indicated Mortality Status at Day 14 and Day 28
NCT01014988 (33) [back to overview]	Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Clinical Chemistry Toxicities
NCT01014988 (33) [back to overview]	Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Hematology Toxicities
NCT01014988 (33) [back to overview]	Number of Participants With the Indicated Ventilation Status: Modality of Supplemental Oxygen Delivery and Mechanical Ventilation
NCT01014988 (33) [back to overview]	Median Time to Resolution of Individual Vital Signs
NCT01014988 (33) [back to overview]	Median Time to Return to Pre-morbid Functional Status
NCT01014988 (33) [back to overview]	Median Change From Baseline (Influenza A or B Quantitative PCR, as Appropriate) in Viral Load at the Indicated Time Points
NCT01014988 (33) [back to overview]	Median Time to Virologic Improvement
NCT01014988 (33) [back to overview]	Number of Participants Who Permanently Discontinued the Study Treatment Due to an AE
NCT01014988 (33) [back to overview]	Number of Participants Who Used Any Concomitant Antibiotic Medications for Complications of Influenza
NCT01014988 (33) [back to overview]	Number of Participants Who Were Permanently Discontinued From the Study Due to an AE
NCT01014988 (33) [back to overview]	Number of Participants With Any Adverse Event (AE) Considered to be Related to Study Treatment
NCT01014988 (33) [back to overview]	Number of Participants With Treatment-emergent (TE) Mutations
NCT01014988 (33) [back to overview]	Number of Participants With Any AE Categorized as an Influenza Complication
NCT01014988 (33) [back to overview]	Number of Participants With Any Severe or Grade 3/4 AEs
NCT01014988 (33) [back to overview]	Number of Participants With Any Severe or Grade 3/4 Treatment-related AE
NCT01014988 (33) [back to overview]	Geometric Mean Area Under the Serum Drug Concentration-time Curve (AUC) Over a 12-hour Dosing Interval (AUC[0-tau]) and AUC Extrapolated to Infinity (AUC[0-inf]) of Zanamivir
NCT01014988 (33) [back to overview]	Geometric Mean Maximum Serum Concentration (Cmax) of Zanamivir at the End of Infusion
NCT01014988 (33) [back to overview]	Geometric Mean Serum Clearance of Zanamivir
NCT01156701 (7) [back to overview]	Number of Patients With Respiratory Outcomes
NCT01156701 (7) [back to overview]	Number of Participants Experiencing Hospitalization or Death Due to Influenza
NCT01156701 (7) [back to overview]	Number of Patients With Any Respiratory Diagnosis
NCT01156701 (7) [back to overview]	Number of Patients With Asthma
NCT01156701 (7) [back to overview]	Number of Patients With Bronchitis
NCT01156701 (7) [back to overview]	Number of Patients With Influenza
NCT01156701 (7) [back to overview]	Number of Patients With Pneumonia
NCT01199744 (10) [back to overview]	Number of Participants With Any Serious Adverse Drug Reaction (ADR)
NCT01199744 (10) [back to overview]	Number of Male and Female Participants With Either a Serious or Non-serious Adverse Drug Reaction
NCT01199744 (10) [back to overview]	Number of Participants in the Indicated Age Categories With Either a Serious or Non-serious Adverse Drug Reaction
NCT01199744 (10) [back to overview]	Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Categorized by Either Having Complications or Having no Complications
NCT01199744 (10) [back to overview]	Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Categorized by Either Having Risk Factors for Influenza or Having no Risk Factors
NCT01199744 (10) [back to overview]	Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Categorized by Reason for the Use of Relenza
NCT01199744 (10) [back to overview]	Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Who Were Also in the Indicated High-risk Categories
NCT01199744 (10) [back to overview]	Number of Participants With Any Adverse Drug Reaction
NCT01199744 (10) [back to overview]	Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Who Were Vaccinated for Influenza
NCT01199744 (10) [back to overview]	Number of Participants With Either a Serious or Non-serious Adverse Drug Reaction Who Were Also Taking Concomitant Medications
NCT01231620 (36) [back to overview]	Number of Participants With the Indicated Clinical Symptoms of Influenza
NCT01231620 (36) [back to overview]	Number of Participants With the Indicated Hematology Values Shifts From Baseline (Day 1) and up to 42 Days
NCT01231620 (36) [back to overview]	Number of Participants With the Indicated Treatment-emergent (TE) Grade (G) 3/4 Clinical Chemistry Toxicities
NCT01231620 (36) [back to overview]	Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Hematology Toxicities
NCT01231620 (36) [back to overview]	Number of Participants With the Indicated Ventilation Status: Modality of Invasive and Non-invasive Ventilator Support and Oxygen Supplementation
NCT01231620 (36) [back to overview]	Serum Concentration of IV Zanamivir
NCT01231620 (36) [back to overview]	Serum Concentration of IV Zanamivir
NCT01231620 (36) [back to overview]	Median Time to Virologic Improvement
NCT01231620 (36) [back to overview]	Median Time to Return to the Pre-morbid Level of Activity as Measured by the 3-point Scale
NCT01231620 (36) [back to overview]	Number of Participants Who Permanently Discontinued the Study Treatment Due to an AE
NCT01231620 (36) [back to overview]	Number of Participants Who Were Permanently Discontinued From the Study Due to an AE
NCT01231620 (36) [back to overview]	Number of Participants With Any Adverse Event (AE) Considered to be Related to Study Treatment
NCT01231620 (36) [back to overview]	Number of Participants With Any Severe or Grade 3/4 AE
NCT01231620 (36) [back to overview]	Number of Participants With Any Severe or Grade 3/4 Treatment-related AE
NCT01231620 (36) [back to overview]	Percentage of Participants With Respiratory Improvement
NCT01231620 (36) [back to overview]	Time to Clinical Response (TTCR) in Participants With Confirmed Influenza
NCT01231620 (36) [back to overview]	Change From Baseline in Quantitative Virus Culture From Nasopharyngeal Swabs Positive at Baseline
NCT01231620 (36) [back to overview]	Change From Baseline in Quantitative Virus Culture From Nasopharyngeal Swabs Positive at Baseline
NCT01231620 (36) [back to overview]	Change From Baseline in the Katz Activities of Daily Living (ADL) Score and Each ADL Activity Score
NCT01231620 (36) [back to overview]	Change From Baseline Viral Load (Influenza A or B) by qPCR From Nasopharyngeal Swabs Positive at Baseline
NCT01231620 (36) [back to overview]	Change From Baseline Viral Load (Influenza A or B) by qPCR From Nasopharyngeal Swabs Positive at Baseline
NCT01231620 (36) [back to overview]	Median Time of Duration of Clinical Symptoms of Influenza
NCT01231620 (36) [back to overview]	Median Time of Duration of Hospitalization and Intensive Care Unit (ICU) Stay
NCT01231620 (36) [back to overview]	Median Time of Duration of Invasive and Non-invasive Ventilator Support and Oxygen Supplementation
NCT01231620 (36) [back to overview]	Median Time to no Detectable Viral RNA and the Absence of Cultivable Virus in Any Obtained Sample (Upper and Lower Respiratory Samples)
NCT01231620 (36) [back to overview]	Median Time to Return to Pre-morbid Functional Status as Measured by the Katz ADL Score and Each ADL Activity Score
NCT01231620 (36) [back to overview]	Median Time to the Absence of Fever and Improved Respiratory Status, Oxygen Saturation, Heart Rate, and Systolic Blood Pressure
NCT01231620 (36) [back to overview]	Number of Participants Assessed as Normal/Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at Baseline (Day 1) and Day 4
NCT01231620 (36) [back to overview]	Number of Participants Who Returned to Their Pre-morbid Functional Status as Assessed Per the Katz ADL Score and Each ADL Activity Score at the End of the Study
NCT01231620 (36) [back to overview]	Number of Participants With All Cause and Attributable Mortality at Day 14, at Day 28, and at the End of Study Visit
NCT01231620 (36) [back to overview]	Number of Participants With Complications of Influenza and Associated Antibiotic Use
NCT01231620 (36) [back to overview]	Number of Participants With no Detectable Viral RNA and the Absence of Cultivable Virus in Lower Respiratory Samples (Bronchoalveolar Lavage Sample [BAL], Endotracheal Aspirate)
NCT01231620 (36) [back to overview]	Number of Participants With no Detectable Viral RNA and the Absence of Cultivable Virus in Lower Respiratory Samples (Bronchoalveolar Lavage Sample [BAL], Endotracheal Aspirate)
NCT01231620 (36) [back to overview]	Number of Participants With no Detectable Viral RNA and the Absence of Cultivable Virus in Lower Respiratory Samples (Bronchoalveolar Lavage Sample [BAL], Endotracheal Aspirate)
NCT01231620 (36) [back to overview]	Number of Participants With Resistance-associated Mutations Detected in the Neuraminidase (NA) and Hemagglutinin (HA) Gene of Influenza A and B Viruses in Nasopharyngeal Swabs and Endotracheal/BAL Samples
NCT01231620 (36) [back to overview]	Number of Participants With the Indicated Chemistry Laboratory Values Shifts From Baseline (Day 1) and up to 42 Days
NCT01527110 (42) [back to overview]	Mean Oxygen Saturation (OS) of Participants Over Period
NCT01527110 (42) [back to overview]	Mean Respiratory Rate (RR) of Participants Over Period
NCT01527110 (42) [back to overview]	Mean Systolic and Diastolic Blood Pressure (SBP and DBP) of Participants Over Period
NCT01527110 (42) [back to overview]	Mean Temperature of Participants Over Period
NCT01527110 (42) [back to overview]	Median Duration of Clinical Symptoms of Influenza Over Period
NCT01527110 (42) [back to overview]	Median Duration of Use of Invasive and Non-invasive Ventilatory Support and Oxygen Supplementation Over Period
NCT01527110 (42) [back to overview]	Median Time to Absence of Fever, Improved Respiratory Status, Improved OS, Improved HR and Improved SBP Over Period
NCT01527110 (42) [back to overview]	Median Time to no Detectable Viral RNA by Quantitative RT-PCR and Viral Culture From Nasopharyngeal Samples Over Period
NCT01527110 (42) [back to overview]	Median Duration of Hospital Stay for the Participants Over Period
NCT01527110 (42) [back to overview]	Number of Participants of Treatment Emergent Toxicities in Clinical Chemistry and Hematology Over Period
NCT01527110 (42) [back to overview]	Number of Participants With Abnormal Clinically Significant Electrocardiograph (ECG) Findings Over Period
NCT01527110 (42) [back to overview]	Number of Participants With and Without Use of Modality of Invasive, Non-invasive Ventilatory Support and Oxygen Supplementation Over Period
NCT01527110 (42) [back to overview]	Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and Grade 4 AE, Grade 3 and 4 Drug-related AE , AE Leading to Discontinuation of Study Drug or From Study, Serious AE (SAE), Drug-related SAE, Fatal AE and Drug-related Fatal AE
NCT01527110 (42) [back to overview]	Number of Participants With Clinical Chemistry Parameters of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Creatine Kinase and Aspartate Amino Transferase (AST) Outside the Normal Reference Range at Any Time During Treatment
NCT01527110 (42) [back to overview]	Number of Participants With Clinical Chemistry Parameters of Albumin and Total Protein Outside the Normal Reference Range at Any Time During Treatment
NCT01527110 (42) [back to overview]	Number of Participants With Clinical Chemistry Parameters of Calcium, Carbon Dioxide Content/ Bicarbonate, Chloride, Magnesium, Potassium, Sodium and Urea/ Blood Urea Nitrogen (BUN) Outside the Normal Reference Range at Any Time During Treatment
NCT01527110 (42) [back to overview]	Number of Participants With Clinical Chemistry Parameters of Creatinine, Direct Bilirubin and Total Bilirubin Outside the Normal Reference Range at Any Time During Treatment
NCT01527110 (42) [back to overview]	Number of Participants With Complications of Influenza and Associated Use of Antibiotics Over Period
NCT01527110 (42) [back to overview]	Number of Participants With Hematology Parameters of Basophiles, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell(WBC) Count, Hemoglobin and Hematocrit Outside the Normal Reference Range at Any Time During Treatment
NCT01527110 (42) [back to overview]	Number of Participants With or Without Treatment Emergent Resistance or Suspected Treatment Emergent Resistance to Zanamivir Over Period
NCT01527110 (42) [back to overview]	Number of Participants With Toxicity Shifts From Baseline in Clinical Chemistry Over Period
NCT01527110 (42) [back to overview]	Number of Participants With Toxicity Shifts From Baseline in Hematology Parameters Over Period
NCT01527110 (42) [back to overview]	Percentage of Participants With Abnormal Clinically Significant ECG Findings Over Period
NCT01527110 (42) [back to overview]	Percentage of Participants With Undetectable Viral RNA and Absence Cultivable Virus From Samples Obtained From Nasopharyngeal Samples Over Period
NCT01527110 (42) [back to overview]	Percentage of Participants With Undetectable Viral RNA and Absence of Cultivable Virus in Lower Respiratory Samples Over Period
NCT01527110 (42) [back to overview]	Number of Participants of Clinical Symptoms of Influenza Over Period
NCT01527110 (42) [back to overview]	Median Duration of Intensive Care Unit (ICU) Stay for the Participants Over Period
NCT01527110 (42) [back to overview]	Median Time to Clinical Response Over Period
NCT01527110 (42) [back to overview]	Median Time to Return to Pre-morbid Level of Activity Over Period
NCT01527110 (42) [back to overview]	Median Time to Virologic Improvement Over Period
NCT01527110 (42) [back to overview]	Mean 50% Inhibitory Concentration (IC50) for Phenotypes of Influenza for the Measure of Viral Susceptibility to Zanamivir at All Visits
NCT01527110 (42) [back to overview]	Mean Change Baseline in Hematocrit at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Albumin and Total Protein at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in ALT, ALP, Creatine Kinase and AST at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Counts of WBC and Platelets at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Creatinine, Direct Bilirubin and Total Bilirubin at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Hemoglobin at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes and Total Neutrophils at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Quantitative Viral Load Measured by RT-PCR From Nasopharyngeal Swabs Positive at Baseline Over Period
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Quantitative Viral Load Measured by Viral Culture From Nasopharyngeal Swabs Over Period
NCT01527110 (42) [back to overview]	Mean Change From Baseline in Sodium, Calcium, Potassium, Chloride, Magnesium, Carbon Dioxide Content/Bicarbonate and Urea/BUN at the Indicated Time Points
NCT01527110 (42) [back to overview]	Mean Heart Rate (HR) of Participants Over Period
NCT01793883 (1) [back to overview]	Time to Alleviation of Influenza Symptoms

Number of Subjects Adhering to Long-term Zanamivir Prophylaxis

Number of subjects taking 80% or more doses per week of zanamivir (10 mg once daily), as influenza prophylaxis, for 13 weeks or longer (as measured by weekly diary and dose counts at study visits). (NCT00784784)
Timeframe: 5 months

Intervention	participants (Number)
Antiviral Prophylaxis	34

Intervention	number of participants with AEs (Number)
TCAD	1
Neuraminidase Inihibitor Monotherapy	1
Open-labeled TCAD	1

Intervention	days (Mean)
TCAD	4.5
Neuraminidase Inhibitor Monotherapy	1
Open-label TCAD	4.7

Intervention	ng*hr/mL (Mean)
TCAD	304
Neuraminidase Inhibitor Monotherapy	1497
Open-lable TCAD	2487

Intervention	participants (Number)
	Day 5 +/-1	Day 10 +/- 1
Neuraminidase Inihibitor Monotherapy	0	0
Open-labeled TCAD	0	1

Intervention	Hours (Geometric Mean)
	ID, 600 mg, CLcr>=80, n=67, 0, 0, 0, 0, 5	ID, 12 mg/kg, CLcr>=80, n=0, 0, 0, 0, 8, 1	ID, 14 mg/kg, CLcr>=80, n=0, 3, 5, 9, 0, 0	MD, 600 mg, CLcr>=80, n=68, 0, 0, 0, 0, 2	MD, 12 mg/kg, CLcr>=80, n=0, 0, 0, 0, 4, 0	MD, 14 mg/kg, CLcr>=80, n=0, 0, 1, 4, 0, 0
Cohort 1: Infants (6 Months to <1 Year of Age)	NA	NA	1.84	NA	NA	NA
Cohort 2: Children (1 to <2 Years of Age)	NA	NA	2.49	NA	NA	1.68
Cohort 3: Children (2 to <6 Years of Age)	NA	NA	1.60	NA	NA	1.76
Cohort 4: Children (6 to <13 Years of Age)	NA	2.57	NA	NA	1.81	NA
Cohort 5: Adolescents (13 to <18 Years of Age)	2.06	2.16	NA	1.73	NA	NA
Cohort 6: Adults (18 Years and Older)	2.39	NA	NA	2.56	NA	NA

Intervention	Liters (L) (Geometric Mean)
	ID, 600 mg, CLcr>=80, n=63, 0, 0, 0, 0, 5	ID, 12 mg/kg, CLcr>=80, n=0, 0, 0, 0, 8, 1	ID, 14 mg/kg, CLcr>=80, n=0, 3, 4, 9, 0, 0	MD, 600 mg, CLcr>=80, n=65, 0, 0, 0, 0, 0	MD, 12 mg/kg, CLcr>=80, n=0, 0, 0, 0, 8, 0	MD, 14 mg/kg, CLcr>=80, n=0, 0, 1, 4, 0, 0
Cohort 1: Infants (6 Months to <1 Year of Age)	NA	NA	3.77	NA	NA	NA
Cohort 2: Children (1 to <2 Years of Age)	NA	NA	3.94	NA	NA	3.77
Cohort 3: Children (2 to <6 Years of Age)	NA	NA	5.15	NA	NA	5.23
Cohort 4: Children (6 to <13 Years of Age)	NA	9.21	NA	NA	9.82	NA
Cohort 5: Adolescents (13 to <18 Years of Age)	18.57	10.09	NA	23.20	NA	NA
Cohort 6: Adults (18 Years and Older)	24.89	NA	NA	24.61	NA	NA

Intervention	Nanomolar (nM) (Mean)
	A/H1N1, Day 1, n=22, 2	A/H1N1, All Post-Baseline, n=8, 1	A/H3N2, Day 1, n=5, 16	A/H3N2, All Post-Baseline, n=2, 3	B, Day 1, n=2, 16	B, All Post-Baseline, n=0, 10
Cohort 6: Adults (18 Years and Older)	0.2091	0.1800	0.2660	0.2300	1.6100	NA

Intervention	Degrees centigrade (Median)
	Day 1, n=87, 43, 7, 11, 12, 27, 14	Day 5, n=73, 42, 7, 6, 9, 15, 10
Cohort 1: Infants (6 Months to <1 Year of Age)	36.8	37.0
Cohort 2: Children (1 to <2 Years of Age)	37.3	36.8
Cohort 3: Children (2 to <6 Years of Age)	37.5	37.3
Cohort 4: Children (6 to <13 Years of Age)	37.3	37.1
Cohort 5: Adolescents (13 to <18 Years of Age)	37.5	37.1
Cohort 6: Adults (18 Years and Older); Zanamivir <=5 Days	37.30	37.00
Cohort 6: Adults (18 Years and Older); Zanamivir >5 Days	37.30	37.15

Intervention	Milliseconds (Median)
	QTcF, Baseline, n=87, 42, 6, 9, 11, 24, 13	QTcF, Day 5, n=68, 40, 0, 1, 3, 3, 5	QTcB, Baseline, n=87, 42, 6, 9, 11, 24, 13	QTcB, Day 5, n=68, 40, 0, 1, 3, 3, 5
Cohort 1: Infants (6 Months to <1 Year of Age)	356.00	NA	412.00	NA
Cohort 2: Children (1 to <2 Years of Age)	362.00	373.00	422.00	416.00
Cohort 3: Children (2 to <6 Years of Age)	365.00	394.00	410.00	444.00
Cohort 4: Children (6 to <13 Years of Age)	387.50	353.00	422.50	380.00
Cohort 5: Adolescents (13 to <18 Years of Age)	387.00	389.00	415.00	399.00
Cohort 6: Adults (18 Years and Older); Zanamivir <=5 Days	400.6	406.6	424.0	422.0
Cohort 6: Adults (18 Years and Older); Zanamivir >5 Days	413.5	405.5	432.0	434.0

Intervention	Days (Median)
	Duration of H, n=130, 7, 11, 12, 27, 14	Duration of H-ICU, n=108, 4, 6, 8, 19, 9
Cohort 1: Infants (6 Months to <1 Year of Age)	7.0	7.5
Cohort 2: Children (1 to <2 Years of Age)	4.0	5.0
Cohort 3: Children (2 to <6 Years of Age)	6.5	5.5
Cohort 4: Children (6 to <13 Years of Age)	6.0	8.0
Cohort 5: Adolescents (13 to <18 Years of Age)	6.5	8.0
Cohort 6: Adults (18 Years and Older)	15.0	11.50

Intervention	Percentage of oxygen level in blood (Median)
	Day 1, n=87, 43, 7, 11, 12, 27, 14	Day 5, n=70, 43, 7, 6, 9, 15, 9
Cohort 1: Infants (6 Months to <1 Year of Age)	98.0	100.0
Cohort 2: Children (1 to <2 Years of Age)	100.0	95.5
Cohort 3: Children (2 to <6 Years of Age)	98.0	97.0
Cohort 4: Children (6 to <13 Years of Age)	98.0	97.0
Cohort 5: Adolescents (13 to <18 Years of Age)	97.5	96.0
Cohort 6: Adults (18 Years and Older); Zanamivir <=5 Days	97.00	97.00
Cohort 6: Adults (18 Years and Older); Zanamivir >5 Days	96.00	96.00

Intervention	Breaths per minute (Median)
	Day 1, n=87, 43, 7, 11, 12, 27, 14	Day 5, n=67, 42, 7, 6, 9, 15, 10
Cohort 1: Infants (6 Months to <1 Year of Age)	32.0	40.0
Cohort 2: Children (1 to <2 Years of Age)	34.0	31.0
Cohort 3: Children (2 to <6 Years of Age)	29.5	30.0
Cohort 4: Children (6 to <13 Years of Age)	20.0	23.0
Cohort 5: Adolescents (13 to <18 Years of Age)	21.0	19.0
Cohort 6: Adults (18 Years and Older); Zanamivir <=5 Days	23.00	20.00
Cohort 6: Adults (18 Years and Older); Zanamivir >5 Days	22.00	23.50

Intervention	Millimeters of mercury (mmHg) (Median)
	SBP, Day 1, n=87, 43, 7, 11, 12, 27, 14	SBP, Day 5, n=73, 43, 7, 5, 9, 15, 10	DBP, Day 1, n=87, 43, 7, 11, 12, 27, 14	DBP, Day 5, n=73, 43, 7, 5, 9, 15, 10
Cohort 1: Infants (6 Months to <1 Year of Age)	102.0	103.0	53.0	60.0
Cohort 2: Children (1 to <2 Years of Age)	100.0	98.0	60.0	60.0
Cohort 3: Children (2 to <6 Years of Age)	105.5	117.0	58.0	67.0
Cohort 4: Children (6 to <13 Years of Age)	108.0	110.0	57.0	68.0
Cohort 5: Adolescents (13 to <18 Years of Age)	107.0	108.5	62.0	54.5
Cohort 6: Adults (18 Years and Older); Zanamivir <=5 Days	126.00	128.00	68.00	70.00
Cohort 6: Adults (18 Years and Older); Zanamivir >5 Days	118.00	132.00	63.00	66.00

Intervention	Participants (Number)
	Normal, n=128, 7, 10, 12, 25, 13	Abnormal NCS, n=128, 7, 10, 12, 25, 13	Abnormal CS, n=128, 7, 10, 12, 25, 13
Cohort 1: Infants (6 Months to <1 Year of Age)	5	2	0
Cohort 2: Children (1 to <2 Years of Age)	7	2	1
Cohort 3: Children (2 to <6 Years of Age)	8	4	0
Cohort 4: Children (6 to <13 Years of Age)	20	5	0
Cohort 5: Adolescents (13 to <18 Years of Age)	8	5	0
Cohort 6: Adults (18 Years and Older)	68	57	7

Intervention	Participants (Number)
	D 1, H ALT, n=129, 71	D 1, N ALT, n=129, 71	D 1, L ALT, n=129, 71	D 5, H ALT, n=102, 45	D 5, N ALT, n=102, 45	D 5, L ALT, n=102, 45	D 1, H DB, n=83, 60	D 1, N DB, n=83, 60	D 1, L DB, n=83, 60	D 5, H DB, n=70, 36	D 5, N DB, n=70, 36	D 5, L DB, n=70, 36	D 1, H TB, n=128, 71	D 1, N TB, n=128, 71	D 1, L TB, n=128, 71	D 5, H TB, n=102, 42	D 5, N TB, n=102, 42	D 5, L TB, n=102, 42	D 1, H Creatinine, n=128, 71	D 1, N Creatinine, n=128, 71	D 1, L Creatinine, n=128, 71	D 5, H Creatinine, n=111, 46	D 5, N Creatinine, n=111, 46	D 5, L Creatinine, n=111, 46
Cohort 6: Adults (18 Years and Older)	48	79	1	41	60	1	17	61	2	20	46	1	11	110	7	13	85	4	27	50	51	31	46	34
Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years)	21	49	1	16	27	1	9	45	3	4	28	1	13	50	7	6	32	2	6	56	9	7	34	5

Intervention	Participants (Number)
	D 1, H Hemoglobin, n=130, 71	D 1, N Hemoglobin, n=130, 71	D 1, L Hemoglobin, n=130, 71	D 5, H Hemoglobin, n=114, 47	D 5, N Hemoglobin, n=114, 47	D 5, L Hemoglobin, n=114, 47	D 1, H TN, n=123, 70	D 1, N TN, n=123, 70	D 1, L TN, n=123, 70	D 5, H TN, n=106, 45	D 5, N TN, n=106, 45	D 5, L TN, n=106, 45	D 1, H WBC Count, n=130, 71	D 1, N WBC Count, n=130, 71	D 1, L WBC Count, n=130, 71	D 5, H WBC Count, n=114, 47	D 5, N WBC Count, n=114, 47	D 5, L WBC Count, n=114, 47
Cohort 6: Adults (18 Years and Older)	0	48	82	1	25	88	51	59	13	49	49	8	29	71	30	50	49	15
Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years)	1	30	40	0	16	31	34	29	7	20	18	7	9	42	20	12	30	5

Intervention	Participants (Number)
	Died on or before Study Day 14, No	Died on or before Study Day 14, Yes	Died on or before Study Day 28, No	Died on or before Study Day 28, Yes
Cohort 1: Infants (6 Months to <1 Year of Age)	7	0	7	0
Cohort 2: Children (1 to <2 Years of Age)	11	0	10	1
Cohort 3: Children (2 to <6 Years of Age)	12	0	12	0
Cohort 4: Children (6 to <13 Years of Age)	26	1	26	1
Cohort 5: Adolescents (13 to <18 Years of Age)	12	2	11	3
Cohort 6: Adults (18 Years and Older)	113	17	108	22

Intervention	Participants (Number)
	ALT, Grade 3, n=128, 69	ALT, Grade 4, n=128, 69	TB, Grade 3, n=127, 69	TB, Grade 4, n=127, 69	Creatinine, Grade 3, n=129, 69	Creatinine, Grade 4, n=129, 69
Cohort 6: Adults (18 Years and Older)	10	5	3	3	6	5
Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years)	1	0	1	4	3	2

Intervention	Participants (Number)
	Hemoglobin, Grade 3, n=129, 69	Hemoglobin, Grade 4, n=129, 69	TN, Grade 3, n=122, 68	TN, Grade 4, n=122, 68	WBC count, Grade 3, n=129, 69	WBC count, Grade 4, n=129, 69
Cohort 6: Adults (18 Years and Older)	40	9	0	1	2	2
Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years)	12	2	3	2	1	0

Intervention	Participants (Number)
	AT on Study, Machine-Assisted: ECMO	AT on Study, Machine-Assisted: Endotracheal	AT on Study, SOD	Day 1, Machine-Assisted: ECMO	Day 1, Machine-Assisted: Endotracheal	Day 1, SOD
Cohort 1: Infants (6 Months to <1 Year of Age)	0	3	3	0	2	1
Cohort 2: Children (1 to <2 Years of Age)	1	5	5	1	3	3
Cohort 3: Children (2 to <6 Years of Age)	0	4	7	0	4	1
Cohort 4: Children (6 to <13 Years of Age)	2	14	13	2	11	6
Cohort 5: Adolescents (13 to <18 Years of Age)	1	4	5	1	4	1
Cohort 6: Adults (18 Years and Older)	4	74	91	3	60	46

zanamivir

Description

Cross-References

Synonyms (123)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (39)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (9)

Molecular Functions (7)

Ceullar Components (22)

Bioassays (917)

Research

Studies (1,133)

Market Indicators

Research Demand Index: 73.91

Study Types

Clinical Trials (25)

Trial Overview

Trial Outcomes

Number of Subjects Adhering to Long-term Zanamivir Prophylaxis

Number of Laboratory Confirmed Influenza Infections

Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption

Days on Supplemental Oxygen

Duration of Hospitalization

Duration of Symptoms

Frequency of Confirmed Pneumonia

Number of Deaths

Number of Participants With ICU Admissions

Number of Participants With Intubations

Number of Participants With Viral Load Decrease as a Function of Time

Number of Participants With Viral Resistance as a Function of Drug Exposure

Pharmacokinetics (AUC0-last) of TCAD

Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1

Geometric Mean Terminal Half Life (t1/2) of Zanamivir

Geometric Mean Volume of Distribution (Vd) of Zanamivir

Mean Viral Susceptibility to Zanamivir at Baseline (Day 1) and All Post-Baseline Visits Collectively

Median Body Temperature at Baseline (Day 1) and Day 5

Median Time to Clinical Response (Sustained Resolution) of All Vital Signs (Composite)

Median Corrected QT Interval (QTc) for Heart Rate by Fridericia's Formula (QTcF) and Bazett's Formula (QTcB) at Baseline (Day 1) and Day 5

Median Duration of Hospitalization and Intensive Care Unit (ICU) Stays

Median Heart Rate at Baseline (Day 1) and Day 5

Median Oxygen Saturation Measured Via Transcutaneous Oximetry (TCPO2) at Baseline (Day 1) and Day 5

Median Respiration Rate at Baseline (Day 1) and Day 5

Median Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline (Day 1) and Day 5

Number of Participants Assessed as Normal/Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at Baseline (Day 1)

Number of Participants With the Indicated Clinical Chemistry Values Relative to the Normal Range at Baseline (Day 1) and Day 5

Number of Participants With the Indicated Hematology Values Relative to the Normal Range at Baseline (Day 1) and Day 5

Number of Participants With the Indicated Mortality Status at Day 14 and Day 28

Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Clinical Chemistry Toxicities

Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Hematology Toxicities

Number of Participants With the Indicated Ventilation Status: Modality of Supplemental Oxygen Delivery and Mechanical Ventilation

Median Time to Resolution of Individual Vital Signs

Median Time to Return to Pre-morbid Functional Status

Median Change From Baseline (Influenza A or B Quantitative PCR, as Appropriate) in Viral Load at the Indicated Time Points

Median Time to Virologic Improvement

Number of Participants Who Permanently Discontinued the Study Treatment Due to an AE

Number of Participants Who Used Any Concomitant Antibiotic Medications for Complications of Influenza

Number of Participants Who Were Permanently Discontinued From the Study Due to an AE

Number of Participants With Any Adverse Event (AE) Considered to be Related to Study Treatment

Number of Participants With Treatment-emergent (TE) Mutations

Number of Participants With Any AE Categorized as an Influenza Complication

Number of Participants With Any Severe or Grade 3/4 AEs

Number of Participants With Any Severe or Grade 3/4 Treatment-related AE

Geometric Mean Area Under the Serum Drug Concentration-time Curve (AUC) Over a 12-hour Dosing Interval (AUC[0-tau]) and AUC Extrapolated to Infinity (AUC[0-inf]) of Zanamivir

Geometric Mean Maximum Serum Concentration (Cmax) of Zanamivir at the End of Infusion

Geometric Mean Serum Clearance of Zanamivir

Number of Patients With Respiratory Outcomes

Number of Participants Experiencing Hospitalization or Death Due to Influenza

Intervention	Days (Median)
	Afebrile Status, n=120, 7, 11, 7, 24, 13	Respiratory Status, n=89, 7, 10, 12, 23, 9	HR, n=121, 7, 11, 12, 27, 13	SBP, n=128, 7, 11, 12, 27, 14
Cohort 1: Infants (6 Months to <1 Year of Age)	4.0	5.0	2.0	2.0
Cohort 2: Children (1 to <2 Years of Age)	2.0	2.0	2.0	2.0
Cohort 3: Children (2 to <6 Years of Age)	25.0	3.5	2.0	2.0
Cohort 4: Children (6 to <13 Years of Age)	3.0	3.0	2.0	2.0
Cohort 5: Adolescents (13 to <18 Years of Age)	3.0	2.0	2.0	2.0
Cohort 6: Adults (18 Years and Older)	3.0	8.0	2.0	2.0

Intervention	Days (Median)
Cohort 6: Adults (18 Years and Older)	10.0
Cohort 1: Infants (6 Months to <1 Year of Age)	8.0
Cohort 2: Children (1 to <2 Years of Age)	3.0
Cohort 3: Children (2 to <6 Years of Age)	5.0
Cohort 4: Children (6 to <13 Years of Age)	5.5
Cohort 5: Adolescents (13 to <18 Years of Age)	4.0

Intervention	Log10 copies per milliliter (Median)
	Day 2, n=89, 0, 0, 2, 3, 2	Day 3, n=82, 4, 7, 10, 15, 7	Day 4, n=84, 0, 0, 2, 2, 1	Day 5, n=75, 5, 4, 8, 12, 5	Day 7, n=23, 1, 1, 1, 3, 1	Day 10, n=19, 0, 2, 1, 4, 1	PT +2 days, n=32, 0, 1, 2, 6, 3	PT +5 days, n=26, 0, 2, 0, 5, 2	PT +9 days, n=27, 0, 1, 0, 3, 2	PT +16 days, n=21, 0, 1, 0, 4, 1	PT +23 days, n=21, 2, 4, 0, 4, 0
Cohort 1: Infants (6 Months to <1 Year of Age)	NA	-1.655	NA	-2.720	-1.820	NA	NA	NA	NA	NA	-4.455
Cohort 2: Children (1 to <2 Years of Age)	NA	-1.930	NA	-3.705	-6.200	-5.385	-6.200	-5.385	-6.200	-2.950	-4.670
Cohort 3: Children (2 to <6 Years of Age)	-3.750	-2.215	-4.895	-3.285	-3.030	-6.430	-2.495	NA	NA	NA	NA
Cohort 4: Children (6 to <13 Years of Age)	-1.160	-1.330	-2.060	-2.930	-3.040	-4.760	-3.825	-4.190	-4.190	-3.825	-3.825
Cohort 5: Adolescents (13 to <18 Years of Age)	-2.280	-2.550	-2.550	-2.550	-1.610	-1.670	-3.060	-3.275	-3.865	-4.610	NA
Cohort 6: Adults (18 Years and Older)	-0.92	-1.42	-1.59	-1.57	-1.58	-1.75	-1.38	-1.84	-2.58	-2.48	-2.89

Intervention	Participants (Number)
	Known Zanamivir-Resistant NA Mutations	Novel NA Mutations	Resistant HA Mutations	Novel HA Mutations
Cohort 6: Adults (18 Years and Older)	0	5	2	4

Intervention	Micrograms*hour per milliliter (Geometric Mean)
	AUC(0-inf), ID, 600 mg, CLcr>=80, n=63,0,0,0,0,5	AUC(0-inf), ID, 12 mg/kg, CLcr>=80, n=0,0,0,0,8,1	AUC(0-inf), ID, 14 mg/kg, CLcr>=80, n=0,3,4,9,0,0	AUC(0-tau), MD, 600 mg, CLcr>=80, n=65,0,0, 0,0,2	AUC(0-tau), MD, 12 mg/kg, CLcr>=80, n=0,0,0,0,4,0	AUC(0-tau), MD, 14 mg/kg, CLcr>=80, n=0,0,1,4,0,0
Cohort 1: Infants (6 Months to <1 Year of Age)	NA	NA	75.31	NA	NA	NA
Cohort 2: Children (1 to <2 Years of Age)	NA	NA	72.42	NA	NA	68.20
Cohort 3: Children (2 to <6 Years of Age)	NA	NA	80.28	NA	NA	81.02
Cohort 4: Children (6 to <13 Years of Age)	NA	107.21	NA	NA	90.33	NA
Cohort 5: Adolescents (13 to <18 Years of Age)	91.07	135.22	NA	64.52	NA	NA
Cohort 6: Adults (18 Years and Older)	82.86	NA	NA	90.33	NA	NA

Intervention	Micrograms per mL (Geometric Mean)
	ID, 600 mg, CLcr>=80, n=67, 0, 0, 0, 0, 6	ID, 12 mg/kg, CLcr>=80, n=0, 0, 0, 0, 9, 3	ID, 14 mg/kg, CLcr>=80, n=0, 4, 5, 9, 0, 0	MD, 600 mg, CLcr>=80, n=72, 0, 0, 0, 0, 2	MD, 12 mg/kg, CLcr>=80, n=0, 0, 0, 0, 4, 0	MD, 14 mg/kg, CLcr>=80, n=0, 0, 1, 4, 0, 0
Cohort 1: Infants (6 Months to <1 Year of Age)	NA	NA	36.21	NA	NA	NA
Cohort 2: Children (1 to <2 Years of Age)	NA	NA	37.78	NA	NA	38.01
Cohort 3: Children (2 to <6 Years of Age)	NA	NA	41.54	NA	NA	43.19
Cohort 4: Children (6 to <13 Years of Age)	NA	44.16	NA	NA	45.18	NA
Cohort 5: Adolescents (13 to <18 Years of Age)	34.47	4.99	NA	25.73	NA	NA
Cohort 6: Adults (18 Years and Older)	32.77	NA	NA	35.30	NA	NA

Intervention	patients (Number)
	Influenza	Asthma	Chronic obstructive pulmonary disease (COPD)	Exacerbation of COPD	Bronchospasm	Pneumonia	Bronchitis	Sinusitis	Otitis media	Any of the above
Cohort 1: Prophylaxis With Untreated Index	3	1	0	0	0	2	8	1	2	16
Cohort 2: Prophylaxis With Treated Index	10	5	0	0	0	1	15	20	4	50
Cohort 3: Untreated With Untreated Index	2539	1488	153	34	110	541	2572	2708	1582	10166
Cohort 4: Untreated With Treated Index	93	54	3	0	5	16	96	140	64	420

Intervention	patients (Number)
	Hospitalization	Death
Cohort 1: Prophylaxis With Untreated Index	0	0
Cohort 2: Prophylaxis With Treated Index	6	0
Cohort 3: Untreated With Untreated Index	1063	4
Cohort 4: Untreated With Treated Index	41	0

Intervention	patients (Number)
	Respiratory Diagnosis	No Respiratory Diagnosis
Cohort 1: Prophylaxis With Untreated Index	16	241
Cohort 2: Prophylaxis With Treated Index	50	957
Cohort 3: Untreated With Untreated Index	10166	153550
Cohort 4: Untreated With Treated Index	420	6305

Intervention	patients (Number)
	Asthma	No Asthma
Cohort 1: Prophylaxis With Untreated Index	1	256
Cohort 2: Prophylaxis With Treated Index	5	1002
Cohort 3: Untreated With Untreated Index	1488	162228
Cohort 4: Untreated With Treated Index	54	6671